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The Sjögren-Larsson syndrome (SLS) is hallmarked by a triad of clinical symptoms, 
namely ichthyosis, spasticity and mild-to-moderate intellectual disability. Though 
convincing clinical descriptions of Sjögren-Larsson patients can be found in literature 
dating back to 1935,1 it was the Swedish psychiatrist and geneticist Torsten Sjögren 
(1896 - 1974) who in 1956 defined the combination of these symptoms as a new 
clinical entity.2 Together with Tage Larsson (1905 - 1998) he made a report in 1957 
upon a cohort of 28 patients with these cardinal symptoms and unraveled its 
autosomal recessive mode of inheritance.3 The original Swedish study cohort was 
later expanded to a total of 58 patients originating from 41 families and again used to 
increase awareness and understanding of this rare neurocutaneous disorder.4 
Although SLS is still considered a rare disease, the prevalence reported here (8.3 per 
100,000) was relatively high due to significant consanguinity within the study 
population. 
Additional reports from partially different and genetically unrelated patients improved 
insights into the disease, creating a clinical picture with variable predominance, 
especially towards the degree of spasticity and ichthyosis.5,6 Furthermore, additional 
clinical features were described such as premature birth, a peculiar crystalline 
maculopathy and impaired speech–language performance.7,8
 In the majority of the patients, the ichthyosis is congenital or develops very early in life. 
It has a generalized distribution pattern and the central face is often spared. The striking 
pruritic character of the ichthyosis in SLS differentiates it from other cornification 
disorders.
 Neurological symptoms gradually appear in the first 2 years of life and are often 
described as a spastic diplegia or tetraplegia with subsequent contractures and 
wheelchair dependency. Also, a delayed and disturbed acquisition of speech and 
language skills becomes apparent along with subsequent limitations in communication. 
Intellectual disability is described as mild to moderate.
 In early childhood, a peculiar crystalline macular dystrophy develops in patients 
with SLS characterized by glistening macular dots. Clinically, this maculopathy is 
accompanied by decreased visual acuity and by photophobia.7 
Biochemical studies
In 1988, Rizzo et al. discovered the primary biochemical defect in SLS.9  Cultured skin 
fibroblasts from Swedish SLS patients showed a defective oxidation of the fatty 
alcohol hexadecanol into fatty acid indicating a defect in fatty alcohol metabolism. 
The deficiency of the microsomal fatty aldehyde dehydrogenase (FALDH) proved to 
be the underlying biochemical defect in SLS.  The subsequent accumulation of both 
12
fatty aldehydes and alcohols in tissues was considered the principal causative 
mechanism leading to the overall clinical phenotype of SLS.10
 In the following years, Rizzo et al. unraveled much from what is now known as 
human fatty alcohol and aldehyde metabolism, by using some of the pathophysio-
logical concepts derived from SLS.11-13
 To gain an insight on the complexity of the biochemical pathogenesis in SLS and 
find new approaches for therapy, an understanding of FALDH and the role that in 
plays in SLS is needed. 
Fatty alcohol and aldehyde metabolism
fatty (or long-chain) alcohols are formed in nature usually as waxes (e.g. beeswax or 
plant waxes) which are esters from fatty acids and fatty alcohols. Vegetables and 
fruits are the major dietary sources of fatty alcohols. However, the human intestine 
eliminates most fatty alcohols after ingestion by direct oxidation into fatty acids.13
 In the human body cells synthesize fatty alcohols as well, mainly to act as substrate 
for the production of wax esters and ether glycerolipids. In the skin, for instance, wax 
esters are used for lubrification and protection. Ether glycerolipids, a subgroup of 
phospholipids, are mainly found in specific tissues such as tissues of the skin, heart, 
brain and myelin.12 In total, fatty alcohols and aldehydes only comprise a very small 
portion of the total lipid composition of human tissues.
 Fatty alcohols are synthesized from fatty acids through the formation of acyl-CoA 
which in turn is used by the enzyme fatty acyl-CoA reductase (FAR) to produce the 
fatty alcohols. The excess of fatty alcohols produced is recycled back into fatty acids 
to prevent accumulation. This step completes the process referred to as the fatty 
alcohol cycle. This reaction is catalyzed by the fatty alcohol: nicotinamide adenine 
dinucleotide oxidoreductase (FAO). FAO is a multi-enzyme complex consisting of the 
two consecutive enzymes fatty alcohol dehydrogenase (FADH) and fatty aldehyde 
dehydrogenase (FALDH). FADH converts fatty alcohols into aldehydes which in turn 
are oxidated to acids by FALDH. Bodily cells have different capacities to synthesize 
fatty alcohols mainly depending upon tissue type and its need for wax esters or ether 
glycerolipids. This capacity is mainly regulated by the coordinating enzymes FAR 
and FAO. For instance, in keratinocytes, where the productive capacity of wax esters 
is high, high activities of FAR and low activities of FAO are seen. On the contrary, liver 
cells display low activities of FAR and high activities of FAO.
The complete fatty alcohol cycle is given in Figure 1.
In addition to its role in the breakdown of fatty aldehydes from wax ester and ether 
glycerolipid metabolism described previously, FALDH is also involved in the breakdown 
of fatty aldehydes from the following lipid pathways, as indicated by research and 
depicted in Figure 2.
13
G
en
er
al
 in
tr
od
uc
tio
n 
&
 o
ut
lin
e 
of
 t
he
 t
he
si
s
1
1. Branched chain alcohols
Phytol, a dietary derived fatty alcohol, is oxidized into the fatty aldehyde phytal which 
subsequently is oxidized by FALDH into phytanic acid. Phytanic acid is catabolized 
into the aldehyde pristanal which again is oxidated into pristanic acid by FALDH.14
 Furthermore, farnesol and geranyl-geraniol are both fatty alcohols which function 
as intermediates in the synthesis of cholesterol and glycoproteins from mevalonic 
acid. Both alcohols are depended upon FALDH for its breakdown by oxidation.14
2. Sphingosine-1-P
Ceramides are lipid molecules made of sphingosine and fatty acids. The lipids found 
in the stratum corneum that lubricate the skin are comprised of these ceramides and 
play part in the formation of the water barrier that protects the skin from water leaking. 
Figure 1  The fatty alcohol cycle. From Rizzo et al.13 
The cycle consists of the following enzymes:
1:  acyl-CoA synthetase 
2:  fatty acyl-CoA reductase (FAR)
3:  FAO complex consisting of 3a: fatty alcohol dehydrogenase (FADH)  
and 3b: fatty aldehyde dehydrogenase (FALDH) 
4: wax synthase 
5:  alkyl-DHAP-synthetase 
6:  alkylglycerol monooxygenase 
7:  lysoplasmalogenase 
8:  fatty aldehyde reductase
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 Intracellular catabolism of ceramides generates sphingosine-1-P. Its subsequent 
degeneration produces hexadecenal which needs FALDH for its breakdown into fatty 
acids.15
3. Fatty acid omega (ω) oxidation
Omega oxidation is an alternative pathway to mitochondrial beta oxidation in the 
process of fatty acid metabolism which takes place in the endoplasmatic reticulum. 
During the process the acid is oxidized into an alcohol which subsequently is catalyzed 
by an alcohol dehydrogenase and by an aldehyde dehydrogenase to generate the 
end product- a dicarboxylic acid. 
 Again, FALDH has shown to play a role in the ω-oxidation of specific fatty acids. 
This role is eminent in the breakdown of the pro-inflammatory mediator leukotriene B4 
(LTB4). FALDH is needed for the inactivation of LTB4 by the oxidation of 20-CHO-LTB4 
into 20-COOH-LTB4. Deficiency of FALDH in SLS results in the accumulation of LTB4 
and its metabolites as was demonstrated earlier by our study group.16,17
Faldh deficiency in SLS
In SLS, the deficient activity of FALDH results in a defective functioning of FAO and 
consequently culminating in the accumulation of both fatty aldehydes and alcohols 
in tissues. As demonstrated here, FALDH is involved in several lipid pathways that are 
also more prevalent in the central nervous system and the skin which correspond 
with the main organ systems affected in SLS. In the last few decades many different 
studies have reported on the accumulation of specific metabolites in SLS and have 
deducted possible clinical consequences. However, the precise biochemical 
mechanisms responsible for all or some of the clinical features in SLS remain largely 
to be elucidated. In general, it is now believed that clinical symptoms evolve from one 
of the following two factors: (1) an accumulation of (toxic) lipid metabolites which cannot 
be metabolized by FALDH (or FAO), their diversion into other metabolic products or a 
combination of both, or (2) the deficiency of critical fatty acid products of FALDH.18
Genetic studies
In 1996, the genetic basis of SLS was unraveled by De Laurenzi et al.19 The FALDH 
coding gene, recently renamed ALDH3A2, is located on chromosome 17p11.2, it consists 
of 11 exons and spans about 31 kb. The amount of ALDH3A2 mRNA produced 
corresponds to the FALDH activity. The mutations seen in SLS mostly result in a 
complete loss of mRNA production and consequently the loss of FALDH activity as 
well, although some mutations with residual FALDH activity have been reported.20
 By now, more than 70 different mutations in the ALDH3A2 gene have been 
identified in SLS patients from around 120 different families. Most mutations in SLS 
15
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are scattered throughout the ALDH3A2 gene and they are generally private mutations, 
occurring in single cases. This makes it hard to study the correlation between 
genotype and phenotype. Original reports from the Swedish study cohort showed 
little variation in phenotype among patients with consanguinity. However, some 
reports have been made by multiple cases within the same family that relevant 
differences in corresponding phenotypes are spotted even though these cases 
share the same genotype and genetic background due to them being from the same 
family.21,22 Other factors such as genetic background and environment probably play 
a part in the phenotypic appearance of SLS besides the factor of mutation. 
Outline of the thesis
This thesis is the second Sjögren-Larsson doctoral thesis from the Radboudumc 
Nijmegen. For more than two decades, our research group has studied the clinical, 
biochemical, and genetic aspects of SLS. During the years, we have extend our study 
cohort to more than 30 genetically and biochemically proven SLS patients. 
Figure 2   The central role of FALDH in fatty aldehyde/alcohol metabolism. 
From Rizzo et al.13
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This thesis is divided into four parts.
Part 1 focuses on the daily functioning of patients with SLS. The purpose of this part 
is to provide patients, parents and clinicians a further insight into the clinical course 
of SLS and to provide prognostic information on intellectual disability. Chapter 2 
describes data from a cross-sectional study of motor performance and everyday 
functioning. Chapter 3 provides a detailed insight into cognitive functioning and 
speech-language pathology in SLS. Also, it studies a possible correlation between 
motor performance results from chapter 2 and scores for developmental age, speech- 
language pathology as well as cerebral imaging.
In SLS the central nervous system and the skin are the organ systems mostly affected 
by disturbed fatty alcohol and aldehyde metabolism. The retina is often considered the 
most peripheral part of the central nervous system. Therefore, part 2 focuses on the 
pathognomonic crystalline maculopathy seen in the retina of SLS patients. Chapter 4 
studies morphologic changes in the macula by optical coherence tomography (OCT) 
in order to find out what specific retinal cell layers are involved in SLS. This chapter 
provides an insight into retinal lipid metabolism and forms the basis for a discussion 
towards which retinal cell types could be responsible for the crystalline maculopathy. 
The study in chapter 5 describes the novel finding of a macular pigment deficiency in 
SLS. Macular pigment and its metabolism are used to give better understanding of 
retinal lipid metabolism in SLS.
Part 3 focuses on the skin. Epidermal dysfunction in SLS is rather complex since it 
contains various FALDH depended lipid pathways and hence it offers multiple 
potential approaches to reduce cutaneous symptoms. In chapter 6, a prospective, 
randomized, double-blinded and placebo-controlled trial was performed to assess 
the effect of blocking leukotrienes synthesis upon the general skin condition and 
especially pruritus in SLS.
Part 4 starts with Chapter 7 which gives a state-of-the-art synopsis of current patho-
physiological concepts in SLS mainly based upon original research data from this study 
group. Furthermore, chapter 8 presents a discussion on current insight and future 
perspectives. Chapter 9 summarizes and discusses important findings from this 
thesis in English and Dutch respectively.
17
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Daily functioning in  
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Part one
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Abstract
Sjögren-Larsson syndrome (SLS) is an autosomal recessive neurometabolic disorder 
characterized by spasticity, learning disability, and ichthyosis. To our knowledge, 
there is no detailed report in the literature concerning the functional consequences of 
SLS. Therefore, we performed a cross-sectional study of motor performance and 
everyday functioning in 17 patients with this rare disorder. Nine female and eight male 
patients with SLS (age range 1–35 years) were investigated. Data were obtained by 
structured interview with parents and patients with SLS, a telephone-conducted 
questionnaire, and physical examination. Motor performance was measured by the 
Gross Motor Function Measure; everyday functioning was assessed using the 
Pediatric Evaluation of Disability Inventory and the Vineland Adaptive Behavior Scale. 
In most patients, spasticity was bilaterally present in hamstrings, hip adductors, and 
gastrocnemic muscles. All participants above 7 years had contractures in the lower 
extremities. Limitations were present in all gross motor dimensions, except for lying 
and rolling. 
Participants had developmental ages far below their chronological age. 
This study revealed that patients with SLS have limitations in gross motor performance. 
Although some patients can reach a certain level of independence, most have activity 
limitations and restrictions in their participation in society. 
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Introduction
Sjögren-Larsson syndrome (SLS) is an autosomal recessive disorder originally 
described by Sjögren and Larsson in 1957 and characterized by the clinical triad of 
spastic diplegia or tetraplegia, learning disability and ichthyosis.1–3 SLS is caused by 
a disturbance of lipid metabolism due to a deficiency of microsomal fatty aldehyde 
dehydrogenase (FALDH).4  This enzyme catalyzes the oxidation of fatty aldehydes 
into fatty acids.4,5 The clinical features of SLS are thought to be the result of the 
accumulation of lipid metabolites.4 Congenital ichthyosis is usually the presenting 
symptom of SLS which brings the child to medical attention. Within the first 2 years of 
life, the neurological symptoms gradually appear. Despite the authors’ longstanding 
interest in SLS, motor performance and everyday functioning was never systematically 
studied in detail in our patients. The motor problem described in our studies, and 
those published by others, is generally summarized as spastic di- or tetraplegia, with 
consequences in terms of contractures and wheelchair dependency.1,3 A detailed 
description of daily functioning in SLS would help professionals to provide a basis for 
the prognostic information they give to patients and their parents. 
 The purpose of this study, therefore, was to describe the level of motor performance 
and everyday functioning at the International Classification of Functioning, Disability 
and Health (ICF)6 levels of activities and participation, in patients with SLS. We aimed 
to give more insight into the natural history of SLS to allow for more precise counseling 
of parents. This information could also serve as reference for rehabilitation programs 
and future therapeutic trials. 
Methods
Participants 
Seventeen Dutch patients, from 14 different families, with biochemically and genetically 
proven SLS were investigated. Clinical characteristics of all participants are shown in 
Table 1. They all showed the classical clinical triad of congenital ichthyosis, spasticity 
and learning disability. Informed consent was given by all parents and the study was 
approved by the local Medical Ethical Committee of the Radboud University Nijmegen 
Medical Centre in Nijmegen and Rehabilitation Centre De Hoogstraat, Utrecht, the 
Netherlands. 
Procedure 
Data were obtained by structured interview with parents and children or young adults 
(if possible), a telephone questionnaire, and physical examination. The physical examination 
and structured interview took place at the Rehabilitation Centre De Hoogstraat, 
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Utrecht. Telephone questionnaires were conducted within a period of 4 months from 
the physical examination and structured interview. Data were collected between 
March 2005 and May 2006. 
Measurements 
For the present study, generic measures for children and adolescents were used as 
much as possible. For some variables for which a generic measure did not exist, 
measures primarily designed for patients with cerebral palsy (CP) were used. All 
measurements were performed by the same physician (JV).
Measures of body function and structure (ICF) 
The level of spasticity, contractures, the presence of scoliosis, and ambulatory capacity 
were documented by physical examination. Also, to get an impression of functional 
muscle strength and selectivity of motor control, all participants were asked to squat 
10 times in a standardized way. 
 Spasticity was defined according to Lance: ‘a motor disorder, characterized by a 
velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated 
tendon jerks, resulting from hyper-excitability of the stretch reflex as one component 
of the upper motor neuron syndrome’. 7 For the purpose of this study, we selected the 
modified Ashworth scale (MAS) and the Tardieu Scale to measure spasticity.8,9 
Although the validity of the MAS can be questioned, it is still one of the most commonly 
used methods for assessing spasticity in children and adults. It has been suggested 
that the Tardieu scale is more appropriate to measure spasticity.9–11 The modified 
Tardieu Scale (MTS) quantifies muscle reaction to stretch and the joint angle at two 
specified velocities of stretch: fast passive velocity stretch (V3) and slow passive 
velocity stretch or passive range of motion (V1). The difference between the joint 
angles measured during the slow and fast velocity stretches is considered to be a 
clinical measure of spasticity. During our measurements, it was noticed by the 
examiner that spasticity in the participants was difficult to quantify due to the presence 
of contractures, especially in the older patients. Therefore, because we expected the 
MAS and MTS scores not to be reliable enough, we decided to use the measures 
only to report the presence or absence of spasticity. We, therefore, recoded the MAS 
score and the MTS score in a dichotomized way: ‘0’ for the absence of spasticity and 
‘1’ for the presence of spasticity. If either the MAS or MTS indicated the presence of 
spasticity, it was recorded that spasticity was present. 
 To examine the presence of contractures, the passive range of motion (ROM) of 
the shoulder, elbow, wrist, hips, knees, and ankles was assessed using a goniometer 
with the participant in supine position. Full passive ROM was coded ‘0’, and limited 
ROM, according to the reference values of the Spinal Alignment and Range of Motion 
Measure, was coded as ‘1’.12 Ta
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Measures of activities and participation (ICF) 
Ambulatory ability in our participant was classified using the Gross Motor Function 
Classification System (GMFCS).13 Motor capacity was measured using the Gross 
Motor Function Measure (GMFM). The GMFM measures gross motor function in five 
domains: lying and rolling; sitting; crawling and kneeling; standing; and walking, 
running, and jumping. There is no age limit but all items should be accomplished by 
a 5-year-old with typical psychomotor development.14 
 To assess everyday functioning the Pediatric Evaluation of Disability Inventory 
(PEDI) and the Vineland Adaptive Behavior Scale (VABS) were used.15,16 Both 
questionnaires were conducted by telephone interview. The PEDI is a parental 
questionnaire that measures both capability and performance of routine daily 
childhood activities in three domains: self-care, mobility, and social function. 
Capability is measured by the identification of functional skills for which the child has 
demonstrated mastery and competence. Performance of daily functional activities is 
measured by the level of caregiver assistance needed to accomplish them. In the 
present study, the Dutch version (PEDI-Nl) was used, which has been shown to be 
reliable and valid.17 The VABS is also a parental questionnaire. It measures the level 
of adaptive functioning in a child or adolescent with or without disability in four 
specific domains: communication, daily living skills, socialization skills, and motor 
skills. In the present study, the self-care and mobility domains of the PEDI and the 
communication, daily living skills, and socialization skills domains of the VABS were 
used. 
Children’s and adolescents’ perspectives 
In cases where the participants with SLS could be interviewed themselves, we asked 
for additional information on the type of school they attended, which sports they 
practiced, their leisure interests, and their own perception of competence. For the 
latter we made use of the Dutch version of the Perceived Competence Scale.18 
Data analysis
Dichotomized scores (0 or 1) for spasticity of adductors, hamstrings, and gastrocnemius 
were counted, giving a possible score of 0 (no spasticity in one of the three muscle 
groups), 1, 2, or 3 (spasticity in three muscle groups) per leg. For the upper extremity, 
scores for biceps and flexors of the wrist were also summarized giving a possible 
score of 0, 1, or 2. 
 To indicate the number of contractures, the presence of contractures in each 
joint for each limb was summarized giving a possible score with a range from 0 to 3. 
 Gross motor function was measured by the GMFM with 88 items scored on a 
4-point Likert scale. For each dimension a percentage score was calculated (child’s 
score/maximum score × 100%). A total score was obtained by adding the percentage 
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scores for each dimension and dividing by the total number of dimensions (five). 
A higher percentage indicates better gross motor capacity. 
 According to the PEDI-manual, we calculated two scores for each domain scale: 
functional skill (FS) score and caregiver assistance (CA) score. These scaled scores 
(0–100) of the PEDI-Nl are used in order to provide an estimate of the child’s 
achievement of activities and amount of care assistance regardless of age. The 
Dutch translation of the VABS survey form was used.16 Descriptive analyses were 
performed for all variables. 
Results
Participant characteristics and test scores at the ICF body function and structure 
level are presented in Table 2a. Of 17 participants, eight were male and nine were 
female. Two sets of siblings participated in this study: patients 5 (age 7y) and 8 (age 
14y), and patients 12 (age 19y) and 13 (age 20y) respectively. Patient ages at the time 
of investigation ranged from 1 to 35 years. In most cases, spasticity was bilaterally 
present in hamstrings, hip adductors, and gastrocnemic muscles. According to the 
measurement protocol in this study, in one adolescent (patient 15) spasticity could 
be confirmed in the gastrocnemii only and three out of 17 participants showed 
spasticity in the upper extremity. All participants above the age of 7 years had 
contractures in the lower extremities, with involvement of three levels (hips, knees, 
and ankles) from the age of 13 years. In one participant (patient 14) contractures were 
present in both elbows. In three participants (patients 10, 16, and 17) scoliosis was 
recorded. The two participants (patients 5 and 13) who were able to squat several 
times were classified at GMFCS Level II. 
Motor functioning 
Ambulatory ability according to the GMFCS is shown in Table 2b and ranged from 
Level II to IV. Percentage scores of all five dimensions and the Total score of the 
GMFM are also shown in Table 2b. All participants had high scores in Dimension A 
(lying and rolling). Sitting (Dimension B) and crawling and kneeling (Dimension C) 
were difficult for most children and adolescents. In children aged 5 years or older only 
two had a maximum score in sitting (patients 5 and 13), and only one had a maximum 
score in crawling and kneeling (patient 5). In these domains all children tried to 
compensate for the impairment of their legs by their arm strength. None of the 
participants achieved a maximum score in Dimension D (standing), or Dimension E, 
walking, running, and jumping. The capacity of walking in all participants was limited 
as the items walking, running, and jumping could only partly be carried out by seven 
out of 14 participants aged 5 years and older. 
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Everyday functioning 
PEDI and VABS data are missing from two patients (5 and 8) who could not be 
contacted by telephone. PEDI scores of the FS and CA scales of 15 participants are 
shown in Table 2b. Both scales range from 0 (minimum) to 100 (maximum) with 
higher scores indicating better performance and increased independence. 
 In the self-care domain, scores of the FS scale varied between 32.8 and 100.0. 
Only two out of six patients older than 18 years of age scored the highest possible 
level. In the CA scale, four out of the six patients older than 18 years of age and one 
child (9 years) scored the highest possible score. In the mobility domain, scores of 
the FS scale varied between 25.5 and 100.0 and in the CA scale between 32.7 and 
100.0. Only one participant (patient 13) scored the highest possible score in the FS 
scale and four participants scored the highest possible score in the CA scale. For 
example, children with the lowest scores in the self-care domain have difficulties with 
items ‘putting on socks and shoes’ and ‘putting on trousers’. In the mobility domain, 
lowest scores refer to difficulties with the items: ‘walking up or down the stairs’, 
‘self-mobility over different kinds of surface’, ‘transfers in and out of a car’, and 
‘cycling’. 
 For the VABS, developmental ages for each domain are calculated and shown in 
Table 2b. In the communication domain, scores for ‘expressive communication’, and 
‘written communication’ were lower than for ‘receptive communication’. For the daily 
living skills domain, scores in ‘domestic’ and ‘community daily living skills’ were lower 
compared with ‘personal daily living skills’. For the socialization domain, all three sub 
domains (‘interpersonal relationships’, ‘play’, and ‘leisure time and coping skills’) 
scores show a large variability. 
Participation of children, adolescents, and young adults with SLS 
All participants required the assistance of parents in the structured interview because 
speech production was affected in all patients. Of the participants aged 4 to 20 years, 
all went to special schools. Of the participants older than 20 years of age, only one 
(patient 13) had found a job in a social working program (special workplace/
environment); the others went to day activity centers. All participants from the age of 
7 years were active in sports. Eleven participants were able to answer questions 
about their perceived competence and they all were very positive about themselves. 
Eleven parents commented specifically on their son’s or daughter’s friendly and 
sociable character. 
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Discussion 
This is the first study that has aimed to describe the level of motor performance and 
everyday functioning in a relatively large series of patients with SLS. Results show a 
large variability in functioning in this group. In line with the recent findings of Lossos 
et al., we found that two adult sisters (patients 12 and 13) differed in their level of 
self-mobility and daily functioning, indicating that phenotypic variability in SLS exists 
within families.19 There seems to be a ceiling effect in motor performance and everyday 
functioning of most participants at or around a developmental age of 12 years. 
 As expected from our standardized neurological examination, we found that 
spasticity, as measured by the MAS and the MTS, was dominantly present in both 
legs in all participants, with only mild impairments in the upper extremities. These 
observations are in line with the original observations made by Sjögren and Larsson.1 
We made an attempt to quantify the level of spasticity but due to the presence of 
Table 2b  Results at ICF activities and participation level.
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
GMFCS level (I-V) III III IV III II III IV III III IV IV IV II IV IV III IV
GMFM  Scores (0-100)
Lying&rolling
Sitting
Crawling& kneeling
Standing
Walk/run/jump
TOTAL (average)
92.2
38.3
11.9
0
0
28.5
96.1
45.0
38.1
0
0
35.8
96.1
78.9
66.7
5.1
0
49.4
100
88.3
78.6
15.4
0
56.5
96.1
100
100
82.1
72.1
90.0
100
90.7
73.8
7.7
0
54.4
94.1
91.2
85.7
46.2
16.7
66.8
70.6
98.3
97.6
64.1
30.8
72.3
96.1
68.3
42.9
10.3
0
43.5
100
26.7
59.5
15.4
12.5
42.7
100
73.3
69.0
0
0
48.5
100
93.3
71.4
7.7
0
54.5
96.1
100
83.3
59.0
52.8
83.3
80.4
16.7
7.1
2.6
0
21.4
100
87.7
66.7
56.4
13.9
64.9
100
88.3
57.1
38.5
13.9
59.6
92.1
13.3
52.4
2.6
0
32.0
PEDI (0-100)
FS scale
Self-care
Mobility
CA scale
Self-care
Mobility
34.1
25.5
26.3
34.9
51.7
32.1
42.6
34.9
32.8
33.2
26.3
32.7
57.7
53.1
26.3
49.7
-
-
-
-
70.1
50.5
100
100
62.0
61.5
68.4
100
-
-
-
-
76.5
59.6
84.0
64.5
64.1
53.1
64.0
62.2
75.4
54.0
66.9
69.3
84.8
54.0
71.1
60.9
100
100
100
100
70.1
45.3
67.6
53.1
93.0
55.8
100
90.7
100
54.9
100
100
83.0
54.9
100
100
VABS 
Communication
Daily skills
Socialization
1:0
0:10
0:9
1:1
0:10
0:10
0:1
0:4
0:1
2:2
1:9
1:9
-
-
-
3:3
3:3
3:3
5:7
2:11
5:5
-
-
-
7:7
5:9
5:11
2:4
3:3
4:6
9:6
8:9
12:3
3:2
5:9
3:6
9:2
15:9
11:6
6:4
5:2
8:2
7:1
6:10
4:10
10:10
12:3
13:6
1:10
5:0
4:4
VABS scores are developmental age (y:mo). PEDI and VABS data missing from Patients 5 and 8 who could 
not be contacted by telephone. ICF, International Classification of Functioning, Disability and Health; 
GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; PEDI, 
Pediatric Evaluation of Disability Inventory; FS scale, functional skills scale scaled scores; CA scale, 
caregiver assistance scaled scores; VABS, Vineland Adaptive Behavior Scales.
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contractures in most participants the MAS and MTS scales could not be administered 
properly. For this reason, no valid conclusion could be drawn about the degree of 
spasticity in patients with SLS. In all participants, ambulatory ability was classified at 
GMFCS Level II, III, or IV, indicating that none of the participants was able to walk 
without restrictions and most of the patients with SLS use a wheelchair to move 
around outdoors and in the community. It is an important finding that none of the 
persons with SLS was severely limited in their self-mobility, even in the long term. In 
five patients, parents reported that their child had been able to walk with or without 
support but gait had deteriorated gradually over time. Sjögren and Larsson found 
that of 24 patients, 12 were unable to walk, five could walk only with support, and six 
others showed marked spasticity in their gait. In the remaining patient, gait was 
‘moderately spastic’. Reports were made about deterioration of gait in four patients 
but no cause for this deterioration was given. In SLS, spasticity might gradually worsen, 
with a subsequent increase in contractures, during the first decades of life.3 
Table 2b  Results at ICF activities and participation level.
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
GMFCS level (I-V) III III IV III II III IV III III IV IV IV II IV IV III IV
GMFM  Scores (0-100)
Lying&rolling
Sitting
Crawling& kneeling
Standing
Walk/run/jump
TOTAL (average)
92.2
38.3
11.9
0
0
28.5
96.1
45.0
38.1
0
0
35.8
96.1
78.9
66.7
5.1
0
49.4
100
88.3
78.6
15.4
0
56.5
96.1
100
100
82.1
72.1
90.0
100
90.7
73.8
7.7
0
54.4
94.1
91.2
85.7
46.2
16.7
66.8
70.6
98.3
97.6
64.1
30.8
72.3
96.1
68.3
42.9
10.3
0
43.5
100
26.7
59.5
15.4
12.5
42.7
100
73.3
69.0
0
0
48.5
100
93.3
71.4
7.7
0
54.5
96.1
100
83.3
59.0
52.8
83.3
80.4
16.7
7.1
2.6
0
21.4
100
87.7
66.7
56.4
13.9
64.9
100
88.3
57.1
38.5
13.9
59.6
92.1
13.3
52.4
2.6
0
32.0
PEDI (0-100)
FS scale
Self-care
Mobility
CA scale
Self-care
Mobility
34.1
25.5
26.3
34.9
51.7
32.1
42.6
34.9
32.8
33.2
26.3
32.7
57.7
53.1
26.3
49.7
-
-
-
-
70.1
50.5
100
100
62.0
61.5
68.4
100
-
-
-
-
76.5
59.6
84.0
64.5
64.1
53.1
64.0
62.2
75.4
54.0
66.9
69.3
84.8
54.0
71.1
60.9
100
100
100
100
70.1
45.3
67.6
53.1
93.0
55.8
100
90.7
100
54.9
100
100
83.0
54.9
100
100
VABS 
Communication
Daily skills
Socialization
1:0
0:10
0:9
1:1
0:10
0:10
0:1
0:4
0:1
2:2
1:9
1:9
-
-
-
3:3
3:3
3:3
5:7
2:11
5:5
-
-
-
7:7
5:9
5:11
2:4
3:3
4:6
9:6
8:9
12:3
3:2
5:9
3:6
9:2
15:9
11:6
6:4
5:2
8:2
7:1
6:10
4:10
10:10
12:3
13:6
1:10
5:0
4:4
VABS scores are developmental age (y:mo). PEDI and VABS data missing from Patients 5 and 8 who could 
not be contacted by telephone. ICF, International Classification of Functioning, Disability and Health; 
GMFCS, Gross Motor Function Classification System; GMFM, Gross Motor Function Measure; PEDI, 
Pediatric Evaluation of Disability Inventory; FS scale, functional skills scale scaled scores; CA scale, 
caregiver assistance scaled scores; VABS, Vineland Adaptive Behavior Scales.
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 Scoliosis was recorded in three patients, but none of these had a severe scoliosis 
or had been operated on. Haddad also found mild spinal deformity was present in his 
group of nine patients with SLS.20 
 We found most patients had difficulties with sitting, crawling, kneeling, and 
standing. One explanation for this might be the presence of contractures. Another 
possible explanation might be a lack of muscle strength in combination with impaired 
selectivity of motor control in the lower extremities. Most children tried to compensate 
for the impairment of their legs with their arms. 
 Developmental ages of the VABS show a large variability, especially in the children 
aged above 5 years (Table 2b). However, all participants had developmental ages 
that were significantly lower than their chronological age and the majority of patients 
had developmental ages that were far below, or around, 12 years. 
 Although some patients reached a certain level of independence, self-care, and 
mobility in an adapted environment, most of them had limited social interaction with 
peers and their participation was restricted. This is in accordance with data from our 
structured interview that showed that only one of the all participants older than 20 
years had a job (in a social working environment), while the rest went to day activity 
centers with special care facilities. 
Limitations of the study 
Several limitations should be considered when interpreting our results. First, due to 
the small sample size, no firm conclusion can be drawn from the findings. Although 
SLS is a very rare disorder we were able to include almost all known patients with SLS 
in the Netherlands. Second, due to lack of more suitable instruments we had to use 
generic instruments and instruments that have been validated only for patients 
with CP. Since the differences between both groups of patients are unknown, results 
must be interpreted carefully. We recommend further research that should focus on 
differences and similarities of patients with SLS and CP. Third, the present study 
design was cross-sectional. SLS is generally considered a non-progressive or only 
very mildly (over decades) progressive neurometabolic disorder. The results of our study 
confirm this hypothesis, but they do not, in the strictest sense, allow us to conclude 
that the consequences for daily functioning and participation are stationary during 
decades. Future prospective longitudinal studies are warranted to document and, 
if possible, predict the course in motor performance and everyday functioning in SLS. 
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Conclusion
In this study, most patients with SLS reached a level of everyday functioning that is 
around or below the level of a typically developing 12-year-old child. Limited 
communication, social interaction with peers, and restricted participation do have an 
impact on the outlook of patients with SLS. Spasticity and contractures, mainly in the 
legs, are major impairments but on the activity level these children and young adults 
are able to move around in the community (GMFCS Levels II–IV). In this cross- 
sectional study there was no sign that indicated a serious loss of motor performance 
or everyday functioning with increasing age. These findings can help professionals to 
provide parents of young children with SLS with general and specific information, to 
guide them to the services they need to minimize the constraints in their development 
and to enhance their quality of life. 
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Abstract
Objective: To describe speech-language pathology in patients with Sjögren-Larsson 
syndrome (SLS) in relation to their cognitive and motor impairment. 
Design: Observational case series. 
Methods: Cognitive functioning was assessed in 16 patients with SLS (nine males; 
seven females) using different neuropsychological tests. Speech-language pathology 
was studied focusing on dysarthria, oral motor functioning, speech intelligibility and 
language development. Potential correlations between speech-language pathology 
and other neurological symptoms (e.g. spasticity) were studied. 
Results: The median cognitive developmental age was 5 years; 8 months (n =13; 
range 3;5 – 8;0) years. A variable degree of mainly pseudo bulbar dysarthria was 
found. Speech intelligibility was influenced by dysarthria, but was also related to 
language pathology. No correlation between motor functioning and dysarthria or 
cognitive development was observed. 
Conclusion: Dysarthria and language problems are important factors in daily life 
functioning of patients with SLS. Based upon the clinical profile found, early speech- 
language therapy is recommended in order to optimize their speech-language 
development. 
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Introduction
Sjögren-Larsson syndrome (SLS) is an autosomal recessively inherited disorder 
characterized by a clinical triad of congenital ichthyosis, spastic di-or tetraplegia and 
mental retardation. It is a rare neurocutaneous disease with a prevalence of < 0.4 per 
100 000. A disturbance of lipid metabolism due to deficiency of the microsomal fatty 
aldehyde dehydrogenase (FALDH) underlies SLS.1-3 
 This enzyme catalyses the oxidation of many medium and long chain fatty 
aldehydes into fatty acids. A deficiency of FALDH results in the accumulation of fatty 
alcohols and aldehydes in body tissues and it is this accumulation that is thought to 
be the main cause of symptoms most clinical in SLS.
 Of all clinical symptoms the ichthyosis is usually the first symptom of SLS. Later 
in childhood the complete clinical picture gradually develops, consisting of spasticity 
in the extremities (diplegia more common than tetraplegia), mental retardation and 
often delayed and disturbed acquisition of speech and language skills with subsequent 
limitations in communication. Many of these patients receive multidisciplinary treatments 
in rehabilitation centers and schools for special education. 
 Cerebral magnetic resonance (MR) imaging shows the presence of a leukoen-
cephalopathy, while MR spectroscopy studies reveal a characteristic peak reflecting 
the accumulation of lipids in cerebral white matter.2 Furthermore, a peculiar crystalline 
retinopathy causes photophobia and subnormal visual acuity and is another early 
symptom of SLS. This retinopathy can be visualized by ophthalmoscopy and is 
mainly characterized by glistening macular dots.4 
 Many of the typical clinical symptoms occurring in SLS have been studied and 
described in the literature during the past decades. However, few data have been 
published regarding the speech language pathology and limitations in communication 
of patients with SLS. 
 In the preparation of this study, an extensive literature search was performed by 
PubMed using Medical Subject Heading (MeSH) database and the search term ‘Sjögren- 
Larsson syndrome’. Besides the general descriptions of impaired speech-language 
performance and pseudo bulbar dysarthria in these patients, this search was unable 
to find any relevant previously published studies.2,3
 The aim of this study is to provide a detailed description of the speech and 
language performance in SLS patients and to study the potential correlation between 
speech-language pathology and other neurological signs and symptoms such as 
spasticity scores and abnormalities on cerebral MR imaging and spectroscopy 
studies. This way, more insight is given into the everyday functioning of these patients, 
which serves professionals involved in their treatment.
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Methods
Participants
This study is part of a larger research project on daily functioning in patients with SLS 
of which results recently have been published.5 The same patients were included in 
the present cross-sectional observational case study, except for one patient who had 
to be excluded because of incomplete data. In all patients the diagnosis SLS had 
been proven at both the genetic and biochemical level. Local medical ethics 
committee approval and parental informed consent were both obtained for all study 
participants. The clinical and biochemical characteristics of the participants are 
summarized in Table 1. 
Procedure
All participants were tested by the same members of this research group. Data were 
obtained by an experienced paediatric neuro-psychologist (BM) and an experienced 
paediatric speech-language pathologist (MG), at the Department of Paediatric 
Neurology of the Radboud University Nijmegen Medical Centre in Nijmegen, The 
Netherlands. For this study, standardized motor function testing of these patients 
took place at Rehabilitation Centre De Hoogstraat in Utrecht, The Netherlands. 
Measurements
Mental performance 
In a previous study the developmental age of the patients was estimated using the 
structured parental interviewing tests Pediatric Evaluation of Disability Inventory 
(PEDI) and Vineland Adaptive Behavior Scales (VABS).5 PEDI and VABS provide an 
estimate of performance in daily life situations.6,7 However, in order to gain further 
insights in neuropsychological development and intelligence of these individuals, the 
cognitive capacity was assessed in this present study using different tests. Cognitive 
tests were selected for the age-range 4–12 years, being the a priori estimated 
developmental age of the participants. Tests used in this study were the Kauffman-ABC 
sub-tests ‘Number Recall’ (auditory memory), ‘Word Order’ (auditory memory and 
motor output) and ‘Hand Movements’ (sequential motor memory) and two sub-tests 
of the verbal intelligence scale of the ‘Leiden Diagnostic Test’ (LDT).8,9 To provide a 
valid assessment of the cognitive capacity, developmental age was assessed for 
each patient such that all five sub-test results scored within ±2 SD from the tests 
norm score at that particular developmental age. 
 Cognitive testing was not performed in patients 1 and 2 because their very young 
ages made testing unreliable.
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Speech-language performance
Dysarthria was scored using the ‘Dysarthria Score’ which is defined in Table 2. The 
Dysarthria Score is an English translation and adaptation of the nationally used Dutch 
‘Nijmegen Dysarthria Scale’ (NDS).10 The NDS is an outcome measurement scale 
which was recently developed by experienced speech language pathologists. It is 
used to systematically score the type and severity of dysarthria in different disease 
Table 1  Clinical characteristics of participants with Sjögren-Larsson syndrome.
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1 1 M 1.2 + + 0 1
2 3 M 0.9 + + 1 NR
3 4 F 1.3 + - 1 1
4 5 M 0.0 + - 1 1
5 6 M 4.7 + - 1 0
6 7 M 3.2 + - 1 0
7 8 F 3.3 + - 1 1
8 9 M 3.8 + - 1 0
9 10 M 3.7 + - 1 0
10 11 F 6.3 + - 1 1
11 12 F 3.7 + - 1 NR
12 13 F 4.5 + - 1 1
13 14 M 5.1 + + 0 0
14 15 F 5.1 + - 0 1
15 16 F 5.2 + - 1 0
16 17 M 2.5 + - 1 1
a  Corresponding patient number in Verhoog et al. 5
b  Sex marked as M (male) or F (female). 
c  Fatty aldehyde oxidation/dehydrogenase (FAO/FALDH) activity, measured using C-18 fatty alcohol as a 
substrate; normal value (n=13), 19.7 to 54.3 pmol/min.mg. 
d  Ichthyosis and seizures noted as present (+) or absent (-).
e  Intensity of periventricular white matter lesions on T2 weighted magnetic resonance (MR) images depicted 
as 0 (moderate), 1 (mild), 2 (absent). 
f  MR-spectroscopy score: height of characteristic lipid peak was compared with N-acetylaspartate (NAA 
peak) and scored as follows: 0 (lipid peak >NAA peak), 1 ( lipid peak < NAA peak), 2 (no lipid peak 
visible), NR (= not recorded).  
Data from e & f were adapted from Willemsen et al.2
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modalities. The NDS evaluates the main physiological speech systems (respiration, 
phonation, resonance, prosody, articulation and lips/ tongue/jaw movements) and 
assesses the effectiveness of speech during communication in daily life. In fact, the 
NDS scoring system is a Dutch revision and translation of the internationally developed 
Therapy Outcome Measures (TOMs). TOMs are a series of 0–5 rating severity scales 
for different aspects of speech-language pathology (including dysarthria) developed in 
the UK by Enderby and John.11 Several reliability research trials have been conducted 
in the UK and confirmed TOMs reliability and reproducibility.12,13 Nationally performed 
research has indicated that the NDS has comparable reliability and reproducibility, 
though further research is pending.14 
 Because most patients with SLS suffer from mild-to-moderate spasticity it was 
expected that dysfunctional movements of lips, tongue and jaw (due to this spasticity) 
would be a major determinant in the dysarthria found in these patients. To test this 
hypothesis it was decided to further specify the dysarthria encountered in these patients 
by scoring the aspects of lips, tongue and jaw movements separately. The results of this 
separate score are indicated in the Oral Motor Score (OMS). Furthermore, to provide 
insight in everyday communicative functioning of these patients, the intelligibility of 
speech was also specified into a separate score (Speech Intelligibility Score; SIS). Both 
OMS and SIS are based upon clinical assessment and elements from the previously 
described Dysarthria Score. 
 Language production and perception tests consisted of the standardized Schlichting 
and Reynell tests used for the younger children and a specific validated Dutch language 
production/perception test (‘Taal test voor Kinderen’) used for the older children.15-17 
The calculated developmental age, determined in the first phase, was used to select 
the proper test. Results of language production and perception tests were converted 
to age equivalents. 
Motor performance and neuro-imaging scores 
Detailed results regarding motor performance in these SLS patients have recently 
been published.5 For the purpose of the present study the results of motor testing 
were modified into a separate 0–12 rating ‘Spasticity score’. This simplified score was 
calculated by summiting the original upper and lower extremity spasticity scores in 
these patients and provided a valid impression of motor functioning (Table 3). 
 Furthermore, in Table 1 the scores were added for cerebral MR imaging and proton 
MR spectroscopy of these patients, which were obtained from another previous study 
in this patient cohort.2 
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Table 2   Dysarthria score.10 Definition describing both functional and 
communicative characteristics of speech. 
Dysarthria 
score
Definition
0 very severe dysarthria/anarthria 
• (Almost) complete loss of capability to move lips, tongue and jaw causing 
inability to produce separate speech sounds. Only some undifferentiated vo-
calization. Aphonia or severely disturbed quality of phonation. Not sufficient 
respiratory support for speech. 
• No effective communication possible.
1 severe dysarthria  
• Extremely disturbed muscle tone and impaired movements of lips, tongue 
and jaw causing production of some open vowels and some clearly aberrant 
consonants. Clearly disturbed quality of phonation. Very slow speech; short 
breathes of speech. 
• Occasionally able to communicate basic needs with familiar persons or trained 
listeners in familiar contexts.
2 moderate/severe dysarthria  
• Clearly disturbed muscle tone and movement abilities of lips, tongue and jaw 
causing aberrant sounding vowels and consonants. Aberrant rate of speech 
and quality of phonation. Aberrant control of breathing during speech. 
• Able to communicate basic needs. Frequent repetition required. Communi-
cation  improves using trained listeners and family members or in familiar set-
tings.
3 moderate dysarthria 
• Minimal disturbance of muscle tone and movement abilities of lips, tongue and 
jaw causing minimal aberrant sounding vowels and consonants. When focus-
ing the patient is able to utter syllables and words correctly. Minimal aberrant 
rate of speech and quality of phonation. Minimally aberrant control of breathing 
during speech. 
• Communication with familiar persons is effective. With some help, communi-
cation with unfamiliar persons may be effective. Capable of communicating 
beyond here and now. Occasional repetition required.
4 mild dysarthria  
• Some minor problems with articulation, quality of phonation and/or control of 
breathing during speech.
• Can be understood most of the time by any listener despite communicative 
irregularities. 
5 no dysarthria  
• Speech according to expectations based upon corresponding chronological 
and developmental age.
• Taking into account both chronological and developmental age as well as 
cultural aspects communication is effective in all situations. 
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Results 
Mental performance
Table 3 depicts both chronological age at time of testing and the assessed 
developmental age. The mean chronological age was 17;10 years. The mean 
developmental age was much lower with a mean of 5;8 (range 3;5 – 8;0) years, 
describing the degree of mental retardation in these patients. In agreement with a 
relatively valid assessed developmental age, the majority of the intelligence subtest 
scores were within ±1 SD of the test’s mean developmental age score, while nearly 
all results were within ±2 SD. 
 Study subject 3 had an estimated developmental age of <2 years. This however 
was not based upon test results and therefore this subject was not included in the 
calculations of mean age and mean developmental age. 
Speeech-language performance
Table 3 summarizes the main test results regarding speech-language performance in 
these SLS patients. 
Speech 
In the greater majority of the study cohort significant dysarthria was found (Dysarthria 
Score ≤4; n =13), predominantly of the pseudo bulbar sub-type (n =10). Most study 
participants were at least moderately affected (Dysarthria Score ≤3; n =10). In two 
participants no dysarthria was found and in three participants the dysarthria was 
severe (Dysarthria Score 1). Two of the latter study participants used alternative forms 
of communication (e.g. speech computer) in daily life. 
 Oral facial motor functioning was impaired in most participants (OMS ≤4; n =15). 
It was noted that most SLS patients in this study cohort have poor functioning of the 
upper facial musculature. Remarkably severe dysphagia was not encountered in 
these patients and accordingly none depended on gastric tube feeding in daily life. 
 Speech intelligibility was likewise impaired in most of the tested participants (SIS 
≤4; n =14). 
Language 
In all participants in whom language could be tested (n =14) at least one language 
production and one language perception test was administered, except for patient 9 
(who could not produce intelligible speech and thus not be tested on production). 
Most of the study participants (n =9) were tested by two different tests for both 
language production and language perception. In these subjects the results of the 
different tests were averaged. 
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 The mean age equivalent for language production was 5;8 (range 2;9 – 8;1) years 
and for language perception 5;6 (range 2;7 – 8;3) years. Thus, the mean ages and 
ranges for the language scores were rather similar to the developmental ages 
depicted earlier. Therefore, in the majority of the study cohort the language problems 
encountered in daily life were most likely strictly related to the global developmental 
delay. This was confirmed by the observation that the specific profile with poor 
language development is most pronounced in those patients with the lowest 
developmental ages. Significant correlations (spearman’s rho) were found between 
developmental age on the one hand and language production (r =0.70; p < 0.01) 
Table 3  Cognitive development and speech-language test results. 
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5 9; 7 5; 6 4/PB 5 2 3; 3 4; 5 4
6 13; 4 7; 0 3/HK+PB 4 4 7; 2 6; 1 6
7 14; 2 5; 0 3/HK 2 4 3; 6 4; 2 6
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a  Dysarthria score ranging from 0 (very severe dysarthria)–5 (no dysarthria); pseudo bulbar (PB) or hypokinetic 
(HK) sub-types are indicated. 
b  Oral motor score ranging from 0 (very severe oral motor dysfunction)–5 (normal oral motor function). 
c  Speech intelligibility score ranging from 0 (very poor speech intelligibility)–5 (clear speech). 
d  Language production and perception. Test scores are depicted as age equivalent (years; months). 
e  Spasticity score ranging from 0 (no spasticity)–12 (severe spasticity in all extremities). 
NR =not recorded. UTR =unreliable test result.
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and language perception (r =0.77; p < 0.001) on the other. The correlation between 
language production and language perception age was even higher (r =0.85; p < 0.001) 
 It was noted that in the older patients the scores on the vocabulary tests were 
relatively high (> +2 SD; patients 9, 11–15). Apparently these patients had continued 
their vocabulary development beyond their language age equivalent. 
Motor performance and neuro-imaging 
Moderate-to-severe spasticity, most commonly in the lower extremities, was encountered 
in the majority of the study group. A possible correlation between spasticity and 
scores for developmental age, dysarthria (Dysarthria Score, OMS and SIS) and MR 
imaging was studied. 
 The individuals with the lowest motor functioning scores (patients 8, 11 and 13) 
were suffering only from a moderate (but not severe) dysarthria and also had only 
moderate oral motor impairment (OMS 2–3). Thus, in contrast to the hypothesis, no 
clear relationship between spasticity score and oral motor score or dysarthria was 
found (correlation coefficients of r = -0.12 and r = -0.06, respectively). 
 The developmental ages of participants 8 and 13 were within ±1 SD from average 
in this study group. Neuro-imaging data in participants 8 and 13 showed distinct 
abnormalities, but other participants with similar neuro-imaging scores did not seem 
to have the same extent of motor function impairment. Also, the participants with the 
best motor functioning (spasticity score 2; patients 9 and 14) differed with respect to 
cognitive functioning (developmental age 4;6 and 8;0 years, respectively) and 
dysarthria and neuro-imaging scores. Furthermore, the participants with the lowest 
developmental ages (patients 9, 11 and 16) had relatively mild neuro imaging scores. 
 In line with these observations, no correlations between extent of motor function 
impairment (spasticity score) and dysarthria (r = -0.06), cognitive impairment (r = -0.08) 
or results of neuroimaging were found when calculated. 
Discussion 
To the best of the authors’ knowledge, this is the first study describing in detail the 
speech-language pathology encountered in SLS patients in relation to their cognitive 
development and spasticity. Detailed knowledge on speech-language development 
and acquisition of communication skills in SLS enables adequate parental counseling 
and optimizes potential benefits of early started speech-language therapy. 
Mental performance
In contrast to most other neurometabolic disorders, SLS is considered a non- 
progressive disorder without any signs of progressive brain disease during childhood 
or early adulthood.3 This is illustrated in this study by the observation that, although 
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all participants suffered from moderate mental retardation, none of the participants 
were severely affected. Also, the mean developmental age of all adult participants 
(chronological age > 18 years; n =6) was strikingly close to the mean of the total 
study group (mean of adult sub-group: 5;7 years; mean total study cohort: 5;8 years). 
Apparently, some kind of ceiling effect in cognitive development (developmental age 
5–6 years) was reached at a certain chronological age without loss of acquired 
cognitive abilities later on in life. Of course, this is a cross-sectional observation and 
thus further longitudinal research is required to confirm this observation. 
Speech-language performance
Although the patients with the poorest speech intelligibility (patients 1, 9 and 16) also 
had the most severe dysarthria, it was found that speech intelligibility was not always 
related to the severity of the dysarthria. For example, patients 3 and 5 suffered only 
from mild-to-absent dysarthria (Dysarthria score 5 and 4) but had relatively poor 
speech intelligibility (SIS 2 and 3) suggesting co-morbidity. In the latter patients, other 
factors such as low developmental age, developmental apraxia of speech and 
phonological problems may have directly influenced the speech intelligibility. Note 
that in patients 4 and 5 language production was severely affected. Phonological 
problems may be part of their co-existing language production impairment and directly 
affect speech intelligibility. 
 In general, it is stated that both dysarthria and language developmental problems 
(related to the cognitive impairment) are important factors determining the speech 
intelligibility in daily life. As stated earlier, no clear relation between motor functioning 
(spasticity) and dysarthria or cognitive development was observed in this study. 
Thus, given the variability in cognitive and speech-language development within 
different levels of motor impairment, it was concluded that it is not likely that spasticity 
is the limiting factor in these children’s cognitive and speech-language development. 
Speech and language therapy (SLT) 
SLT aims to optimize the capabilities of patients with broad ranging disorders to 
communicate and consists of different treatment modalities. Most patients with SLS 
receive therapy from speech-language pathologists. However, the effect of this 
treatment regarding outcome in communicative skills of SLS patients is not clear. 
Because the neurological features of SLS are usually stable, the literature regarding 
the management of speech-language pathology in children with cerebral palsy (CP) 
was studied. Speech-language pathology is common in CP (estimated incidence 
approximately 20%).18 A recent Cochrane Database review showed some positive 
effects on communication skills assigned to SLT in a very diverse patient population 
with CP; conclusive evidence for the beneficial effect of (early) SLT on the improvement 
of communication skills, however, was lacking.19 
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 In The Netherlands a national guideline on CP was recently implemented which 
also covers this topic.20 This guideline proposes early started SLT in children with CP 
to improve speech language performance and thereby daily functioning in these 
patients. Especially children with a disharmonic profile (e.g. low speech intelligibility 
combined with relatively spared cognitive functioning) should receive SLT as early as 
possible. SLT should focus on stimulating the child to actively communicate with its 
communication partners (e.g. siblings and peers) and may involve the use of 
alternative forms of communication (e.g. speech computer). 
 Limitations in communication and restrictions in social participation are important 
factors influencing daily functioning of patients with SLS, as was demonstrated by 
Verhoog et al.5 Realizing the limitations of comparing SLS with a highly diverse patient 
population such as CP, it is believed that starting SLT early could as well be 
advantageous to SLS patients. Based upon the authors’ own experience and the 
above-mentioned beneficial effect of SLT in CP patients, this study therefore proposes 
early started SLT in all patients with SLS. The duration and focus of SLT depends on 
individual progress, speech-language and developmental profile as well as existing 
co-morbidity (e.g. visual impairment). It should involve both patient and parents. 
Progress of speech-language and communication performance should be monitored 
frequently. 
Counseling parents 
This cross-sectional study clearly shows the complex clinical character of SLS. Yet, it 
provides detailed information when counseling the caregivers of a newly diagnosed 
SLS patient. Based upon these findings, the expected clinical profile relating to 
cognitive functioning, speech-language and communication performance as well as 
motor functioning can be drawn. Clinical variability urges one to use prognosis with 
caution. 
Conclusion 
This study provides an overview of the impairment in cognitive development and 
speech-language performance in a relatively large cohort of SLS patients. The tests 
performed in this study show that most of the patients suffer from moderate cognitive 
impairment which typically seems to reach a ceiling at 5–6 years of developmental 
age. There are no signs of progressive neurological disease contrasting to the 
common experience in most other neurometabolic disorders. Cognitive impairment 
is associated with language impairment that is more severe in those patients who 
reached the lowest developmental ages. Almost all patients suffer from a mild-to- 
moderate (pseudo bulbar) dysarthria which influences speech intelligibility and 
aggravates their already poor communicative daily life functioning. Taken together 
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the test results show that impairments in speech-language performance and 
communication are common and important clinical features of SLS. Early started SLT 
may play an important role to optimize speech-language performance and (augmented) 
communication and thereby improve the daily functioning of patients with SLS. 
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Abstract
Purpose: To study morphologic changes in the macula by optical coherence 
tomography (OCT) in patients with a crystalline macular dystrophy due to the auto - 
somal recessive neurocutaneous Sjögren-Larsson syndrome (SLS).
Design: Retrospective observational case series. 
Participants: Twenty-seven eyes of 14 patients, mean age 14.6 (range 3–24) years, 
with biochemically and genetically proven SLS underwent clinical and OCT investigation 
between September 2004 and September 2006. 
Methods: All patients underwent full ophthalmologic examination including slit-lamp 
biomicroscopy and binocular ophthalmoscopy. Optical coherence tomography of all 
eyes was performed using the macular thickness map protocol of Stratus OCT.
Main Outcome Measures: Macular morphology in clinical examination and OCT.
Results: Beside clinically visible perimacular crystalline deposits in all eyes of all 
study participants, macular morphology and reflectivity were significantly changed on 
OCT compared with healthy eyes. We found focal hyperreflectivities in all study eyes 
within the perifoveal ganglion cell layer and the inner plexiform layer, corresponding 
to the clinical localization of retinal crystals. More interestingly, a cystoid foveal 
degeneration on OCT was present in the majority of patients with SLS (18/27 eyes, or 
67% of all eyes studied), varying from multiple micro-cystoid spaces to cystoid foveal 
atrophy. In general, patients who were severely affected on OCT showed intense 
changes on previously performed cerebral magnetic resonance spectroscopy. 
Conclusions: Patients with SLS show a childhood-onset crystalline macular dystrophy 
with cystoid foveal atrophy on OCT in most cases. The intra-retinal deposition of 
lipid metabolites may lead to Müller cell degeneration with subsequent formation of 
cystoid spaces or atrophic changes within the fovea. Because this macular dystrophy 
is present in all examined patients with SLS, familiarity with this maculopathy seems 
important for the diagnosis of this rare systemic disease.
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Introduction
Sjögren-Larsson syndrome (SLS) is an autosomal-recessive, neurocutaneous disorder 
with a prevalence of <0.4 per 100 000 population.1 The disease, which was originally 
described by Sjögren and Larsson in 1957, consists of a clinical triad of spastic diplegia 
or tetraplegia, mental retardation, and ichthyosis.2 Sjögren-Larsson syndrome is 
caused by a disturbed lipid metabolism due to a deficiency of the microsomal fatty 
aldehyde dehydrogenase (FALDH) enzyme, which catalyzes the oxidation of many 
different medium- and longchain fatty aldehydes into fatty acids. Therefore, FALDH 
deficiency results in the accumulation of fatty alcohols and fatty aldehydes in body 
tissues. The accumulation of these lipid metabolites is considered the principal cause 
of the clinical symptoms of SLS.3 In addition to the neurologic symptoms, most SLS 
patients suffer from photophobia and subnormal visual acuity. A crystalline maculopathy, 
which develops gradually within early childhood in patients with SLS, can be observed 
by ophthalmoscopy (Figure 1).4 The crystalline dots are clinically scattered throughout 
the perifovea within the inner retinal layers. Although the central fovea seems to be 
uninvolved by crystal deposition, virtually all SLS patients have subnormal visual 
acuity. We hypothesized the presence of faint changes of the subclinical foveal 
anatomy, which could explain the disturbed visual function. The present paper 
describes the anatomic changes within the fovea of patients suffering from SLS, 
which were perceived by optical coherence tomography (OCT). 
Figure 1  Color fundus photograph representative of the clinical appearance of juvenile 
macular dystrophy in Sjögren-Larsson syndrome. Note the white-yellow perifoveal 
crystals oriented alongside Henle’s layer. The fovea of the patient seems clinically 
unremarkable, which is in contrast with the central cystoid space found on optical 
coherence tomography of the same eye (inset).
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Materials and Methods 
Patients
We included patients with SLS treated at the Department of Pediatric Neurology, 
Radboud University Nijmegen Medical Center, in our retrospective, observational 
case series. Our study was performed at the Department of Ophthalmology, Radboud 
University Nijmegen Medical Center, in accordance with the tenets of the Declaration 
of Helsinki 1975 (1983 revision). Local ethics committee approval was obtained, 
and informed consent to participate in this study was acquired for all subjects. 
In preparation for this study and when finishing our manuscript, we performed an 
extensive literature search by PubMed using the Medical Subject Heading (MeSH) 
database and the search terms “Sjögren-Larsson syndrome,” “tomography, optical 
coherence,” and “macula lutea.” In doing so, we were unable to find any previously 
published literature covering our research topic. All study participants underwent a 
complete ophthalmologic examination, including slit-lamp biomicroscopy, Goldmann 
applanation tonometry, and binocular ophthalmoscopy. If possible, we determined 
the patients’ best-corrected visual acuity. In addition, digital color fundus photographs 
(Imagenet, Topcon Corporation, Tokyo, Japan) of the posterior pole were acquired. 
 We included patients with no other accompanying ocular disorders that could affect 
retinal morphology, such as macular diseases or retinal dystrophies, diabetic retinopathy, 
inflammatory retinal disorders, or increased intraocular pressure. Diagnosis of juvenile 
macular dystrophy in SLS was established by characteristic, intraretinal, glistening 
yellow-white dots in the perimacula of both eyes accompanied by deficient FALDH 
activity in cultured skin fibroblasts and proof of the diagnosis at the genetic level by 
mutation analysis of the FALDH gene as described elsewhere.1,4 
Image acquisition by OCT
We performed OCT scanning with a third-generation OCT (Stratus OCT, Carl Zeiss 
Meditech, Dublin, CA) using the custom software, version 4.0.1, to acquire and analyze 
images. Before OCT examination, sufficient pupil dilation was achieved with 1 drop of 
tropicamide 0.5% and 1 drop of phenylephrine 5%. One OCT image of the central 
retina, consisting of 6 B-scans, was recorded in each eye of the patients. In detail, we 
used radially oriented scans with a scan length of 6 mm and 512 A-scans per B-scan 
(macular thickness map scan protocol of the custom OCT software), resulting in 
approximately 10 µm axial and 12 µm transversal resolution. Only sections through 
the fovea were used for further analysis. Foveal sections were identified by the foveal 
depression and the lack of the inner retinal cellular layers. In addition, the infrared 
video fundus image of the OCT was used to ensure a transfoveal scan. Changes in 
morphology and reflectivity of the retinas of all SLS patients on OCT were analyzed by 
comparison with transfoveal OCT images of healthy maculae from age-matched patients. 
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Cerebral imaging
In a previous study, cerebral magnetic resonance imaging (MRI) and magnetic 
resonance spectroscopy (MRS) results were systematically analyzed for the same 
cohort of patients described here.1 In short, cerebral MRI showed normal brain 
anatomy, but white matter abnormalities in all patients. Cerebral white matter was 
systematically studied and graded normal (0), mildly (1), or severely (2) affected. 
Cerebral MRS showed an abnormal accumulation of lipids compared to a reference 
metabolite (N-acetylaspartate) in white matter that was graded as 0 (no lipid 
resonance visible), 1 (lipid resonance < resonance of N-acetylaspartate), or 2 (lipid 
resonance > N-acetylaspartate).
 Because the retina originates from the diencephalon, one may expect changes 
in both retina and brain in this complex metabolic disease. We therefore compared 
the degree of cerebral abnormalities in MRI and MRS to macular affection on OCT. 
Results
Population
We found 28 eyes of 14 patients from 11 different families eligible to be included in our 
study and we obtained informed consent from all patients. In one eye of one patient, 
the quality of the OCT scan was not suitable for further analysis, and in 14 eyes of 8 
patients we were unable to gain the complete OCT dataset to create a retinal map. In 
all of these eyes, however, we were able to obtain at least one transmacular B-scan 
for a detailed morphological analysis of the fovea. Eventually, a total of 27 (14 right 
and 13 left) eyes of 14 patients (6 male, 8 female; mean age, 14.6 years; range 3–24 
years) were included in our study. 
 All patients showed the classic clinical phenotype of SLS with ichthyosis, spasticity, 
and mental retardation. In addition, a crystalline maculopathy could be detected by 
ophthalmoscopy in all study participants. Figure 2 depicts our major study results, 
including patients’ demographics, visual acuity, and results of OCT, MRI, and MRS.
Optical coherence tomography
The OCT analysis of normal maculae showed the clearly distinguishable bands 
presumed to correlate with the normal anatomic configuration of a healthy macula as 
described elsewhere.5 When compared with healthy eyes, changes in macular OCT 
scans were observed in all eyes of all SLS patients studied. These changes were 
symmetric for both eyes of a study participant in all cases.
 Focal hyperreflective spots on OCT corresponding to retinal crystals were 
observed in all study eyes without exception. The focal increased reflectivities on 
OCT could be observed within inner perifoveal layers of the retina, that is, within the 
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Patient Sex; Age 
(years)
Visual acuity  
OD – OS
Cerebral 
MRI grading
Cerebral 
MRS grading
Grading Image
1 F; 3 NR 2 0 1
2 F; 5 NR 1 0 1
3 M; 8 NR 1 1 2
4 M; 9 NR 1 2 1
5 M; 13 20/125 - 20/125 1 2 3
6 F; 14 20/50 - 20/50 1 1 1
7 M; 15 20/50 – 20/50 1 2 3
8 M; 15 20/50 – 20/40 1 2 3
9 F; 15 20/63 – 20/32 1 1 1
10 F; 19 20/32 – 20/50 1 0 3
11 F; 20 20/32 – 20/40 1 1 2
12 M; 22 20/80 – 20/80 2 2 3
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ganglion cell layer and the inner plexiform layer (Figure 3A). The hyperreflective spots 
were located at the site of the intraretinal yellow-white dots as documented by color 
fundus photographs, and their number increased by a clinically larger number of crystals.
 In 10 eyes of 5 patients an inconsistent number of intraretinal microcystoid 
spaces were present on OCT within the foveal and parafoveal inner retinal layers 
(Figure 3B). An additional 8 eyes of 4 patients showed a single, large cystoid space 
right within the fovea, which was covered by a thin, intermediate to high reflective 
membrane. Occasionally, spots of increased reflectivity, suggesting floating material, 
were observed within these large foveal cystoid spaces (Figure 3C). 
 From comparison of the patients’ OCT scans and the corresponding MRS results, 
one may consider a positive data relationship, because most patients with severe 
macular changes on OCT also revealed strong abnormalities on MRS. However, to 
verify this possible relationship, a larger sample is required to allow statistical analysis. 
Changes on conventional MRI scanning did not show a clear association with the 
OCT results. Because of the small datasets, no statistical analysis was performed.
 We could gain retinal maps in 14 eyes (6 right eyes) of 8 SLS patients (4 males) 
of a mean age of 17 (range 13–24) years. The mean central macular thicknesses were 
144.6±28.8 µm and 146.6±24.9 µm in the right and left eyes, respectively. The mean 
central foveal thickness in our study eyes was thinner than recently published normal 
measurements, which range from 203.8±19.5 µm to 212.0±20 µm.6,7 We were able to 
achieve follow-up maps in 5 eyes (3 patients) after a period of 15±2 months, and 
observed a slight increase in macular thickness on OCT in these eyes. The mean 
central macular thicknesses after 1 year in this subpopulation changed from 
124.8±19.3 µm to 137.7±24.8 µm. 
13 F; 23 20/63 – 20/63 2 1 1
14 F; 24 20/80 – 20/80 1 2 2
Figure 2  Demographics, visual acuities, and imaging results of patients with macular 
dystrophy in Sjögren-Larsson syndrome. To facilitate data comparison, the mild, 
moderate, and severe forms of OCT results are simplified to OCT grades 1, 2, and 3, 
respectively (grading here does not allow any assumptions about retinal function or 
longitudinal disease progression).
F = female; M = male; MRI = magnetic resonance imaging; MRS = magnetic resonance spectroscopy; 
NR = not recordable; OCT = optical coherence tomography; OD = right eye; OS = left eye.
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Figure 3  A. Optical coherence tomography (OCT) view of the mild form of juvenile 
macular dystrophy in Sjögren-Larsson Syndrome (SLS). Note the focal hyperreflectivities 
(arrows) sited at locations of clinically visible intraretinal crystals. The shape of the fovea 
as well as structure and reflectivity of the photoreceptors seem normal. B. An OCT 
view of the moderate form of juvenile macular dystrophy in SLS. The fovea is thinned 
with a trodden shape. Microcystoid intraretinal spaces of low reflectivity emerge within 
the inner parts of the fovea (arrow). C. An OCT view of the severe form of juvenile 
macular dystrophy in SLS. A large cystoid space including some hyperreflective 
spots has appeared within the fovea (asterisk). A thin structure, presumably being a 
complex of the retinal inner limiting membrane and the posterior vitreous membrane, 
covers the foveal cystoid space (arrowhead). A prominent hyperreflective area 
corresponds to the perifoveal crystals observed clinically (arrow). Note the structural 
change and increased reflectivity of the central parts of the photoreceptor inner 
segments–outer segments complex.
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Discussion 
In this paper, we describe a peculiar macular dystrophy in patients suffering from an 
autosomal-recessive inherited deficiency of FALDH that causes a neurocutaneous 
disease called SLS. Beside a thinned central fovea, we found typical changes of the 
macular anatomy on OCT scans in all study participants. We observed focal hyper-
reflectivities, which corresponded to clinically visible intraretinal crystals. Most interestingly, 
we frequently found clinically invisible intra-foveal cystoid changes on OCT scans in 
the majority of our patients.
 The focally increased reflectivity on OCT seems to be located in the perifoveal 
ganglion cell layer and inner plexiform layer. These layers are mainly composed of 
axons and dendrites of ganglion cells and retinal interneurons. The arrangement of 
crystals both on OCT and fundoscopy suggests participation of the perifoveal 
ganglion cells in the deposition of abnormal lipids in SLS. This finding correlates with 
the known involvement of ganglion cells in other lipid storage diseases showing 
fundus abnormalities, for instance in lysosomal storage disorders.8 In the present 
study, no abnormalities were found by fundoscopy in the peripheral parts of the 
retina. Previously described biochemical and metabolic differences between the 
macula and the peripheral parts of the retina may explain this dissimilarity, and an 
increased lipid turnover in the central retina may play a role in the location of the 
crystalline deposits in the perimacula.9,10  
 The development of macular cystoid spaces does not seem to correlate to the 
patients’ age; patients of more or less the same age may have quite different stages 
of cystoid changes. Even within the same family a younger patient may show a more 
severe stage of maculopathy than an older sibling. Furthermore, follow-up OCT in 5 
eyes of 3 patients after a period of 15 months did not reveal any major changes of the 
cystoid macular dystrophy. Individual variation in progression of the maculopathy 
and differences in genetic background may play a part in the creation of this 
heterogenic subclinical picture. 
 According to our present findings, we propose a differentiation of the OCT results 
regarding patients with SLS maculopathy into 3 forms, namely, mild, moderate, and 
severe. In the mild form, the OCT image shows focal perifoveal intraretinal hyper-
reflectivities (Figure 3A). The moderate form of maculopathy is characterized by 
microcystoid changes within the thinned fovea in addition to perifoveal intraretinal 
hyperreflectivities (Figure 3B). Finally, in severe maculopathy, a foveal macrocystoid 
space appears within a ring of strong perifoveal hyperreflectivities (Figure 3C). The thin, 
highly reflective membrane on top of the solitary large cystoid spaces may represent a 
structural complex of the posterior vitreous cortex and the retinal inner limiting membrane. 
 Multiple, small, intraretinal cystoid structures as well as single, large, central 
foveal cystoid spaces were found on OCT and seemed to be located in the outer 
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plexiform layer and inner nuclear layer of the retina. The inner nuclear layer mainly 
contains nuclei and cell bodies of Müller glia cells whereas the outer plexiform layer 
is composed of synapses between photoreceptors and horizontal cells or bipolar 
cells and the cytoplasm of Müller glia cells. The typical localization of the cystoid 
spaces in our patients, together with the only mild-to-moderate loss of visual acuity, 
suggests a major affection of the foveal Müller cells and not the photoreceptors. If 
neuronal retinal cells or photoreceptors would be primarily involved in this macular 
dystrophy, one would expect a more severe visual impairment in these patients. 
Increasing loss of Müller cells with disease progression, however, may lead to foveal 
thinning and eventual formation of a cystoid space under partial preservation of 
visual acuity. We were unable to detect significant changes within fifteen months of 
observation in 3 of 14 study participants. Therefore, we believe that foveal atrophy in 
SLS may be a time-consuming process and a prolonged follow-up period in a larger 
number of patients may be necessary to illustrate disease progression. 
 In pediatric neurology, SLS is considered to be a typical example of a white 
matter disorder, and therefore the affection of oligodendrocytes located in the CNS 
may play a pivotal role in disease development. Müller cells and oligodendrocytes, 
however, share many structural and functional similarities.1,11 The classification of SLS 
as a white matter disorder and the OCT findings in the present study point to the 
Müller cell and the retinal ganglion cell layer as the most probable retinal tissue 
components involved in the pathogenesis of the juvenile macular dystrophy in SLS. 
Here, direct effects of the FALDH enzyme deficiency or the subsequent accumulation 
of fatty alcohols may be the underlying biochemical processes for crystal deposition 
and formation of cystoid spaces.1 
 In conclusion, to the best of our knowledge, we offer the first description of the 
subclinical foveal alterations on OCT in patients with crystalline macular dystrophy in 
SLS. After an extensive literature research, we were unable to find any other reports 
covering this issue. In addition to the perifoveal deposition of intraretinal crystals, a 
cystoid foveal atrophy was visible on OCT. Because the latter was highly variable 
between individual SLS patients, we propose a differentiation into 3 forms to offer a 
simplified description of these microscopic changes. Our study illustrates the 
potential of OCT for determination and ranking of the maculopathy in SLS patients, 
which may allow assumptions about the CNS of SLS patients. Other than MRI and 
MRS, examination by OCT provides a straightforward low-cost approach to the 
outermost part of the CNS, the retina, which may be helpful in future SLS treatment 
trials. 
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Abstract
Purpose: Sjögren-Larsson syndrome (SLS), an autosomal recessive hereditary disorder 
with congenital ichthyosis, spastic diplegia or tetraplegia, and mental retardation, 
reveals a characteristic macular dystrophy with intraretinal crystals and foveal pseudo - 
cysts. Ophthalmic symptoms in SLS are reduced visual acuity and photophobia. This 
article reports the deficiency of macular pigment as a novel finding in this peculiar, 
congenital maculopathy. 
Design: Cross-sectional, observational case study. 
Participants: Patients with clinically and genetically proven SLS. 
Methods: Besides general ophthalmologic examination, 2 different methods were 
used; fundus autofluorescence (FAF) and fundus reflectometry with the macular 
pigment reflectometer (MPR), for measuring macular pigment (MP). 
Main Outcome Measures: Distribution profiles and quantity of MP in eyes of SLS 
patients. 
Results: Twenty-eight eyes of 14 patients were included. The technique to measure 
MP depended on the ability of the mentally handicapped patients to cooperate. 
Fundus autofluorescence images providing qualitative estimates were obtained from 
9 eyes of 5 patients, and MPR measures providing quantitative estimates were 
obtained from 19 eyes of 10 patients. Fundus autofluorescence images of SLS 
patients lacked the typical attenuation of macular FAF signal expected in normal 
eyes. Mean foveal MP levels measured by MPR showed significantly lower values in 
SLS patients (0.10±0.07) than in healthy individuals (0.69±0.17; P<0.001, Student 
t test). 
Conclusions: The group of SLS patients studied here had significantly reduced 
levels of foveal MP. The crystalline macular dystrophy in SLS seems to be the first 
known disease with a genetically caused deficiency of MP.
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Introduction
Sjögren-Larsson syndrome (SLS), as first described by Sjögren and Larsson in 1957, 
is an autosomal recessively inherited disorder characterized by mental retardation, 
spastic diplegia, and congenital ichthyosis.1 The disease is caused by an enzymatic 
defect in lipid metabolism, namely microsomal fatty aldehyde dehydrogenase 
(FALDH) deficiency. Fatty aldehyde dehydrogenase catalyzes the oxidation of many 
different medium-and long-chain fatty aldehydes into fatty acids. Fatty aldehyde 
dehydrogenase deficiency results in the accumulation of fatty aldehydes and fatty 
alcohols in body tissues, which is considered the principal causative mechanism 
leading to the clinical symptoms of SLS. 
 Besides the neurocutaneous features, patients with SLS exhibit a typical 
crystalline juvenile macular dystrophy with onset in childhood, which is characterized 
clinically by reduced visual acuity and photophobia.2 In addition to the crystalline 
deposits located at the inner retinal layers, a cystoid foveal atrophy has been detected, 
possibly based on an underlying Müller cell disorder, by optical coherence tomography 
(OCT).3 
 Macular pigment (MP) is a mixture of 2 carotenoids, lutein and zeaxanthin. The 
concentration4 and spatial distribution5–7 of lutein and zeaxanthin varies greatly 
among individuals. In humans, carotenoids are acquired only through dietary intake. 
Peak concentration of MP depends on many factors, such as geographic location 
and lifestyle, that is, nutritional habits, smoking, and supplemental intake.8–11 
Regardless of the wide ranges of MP concentrations under physiologic circumstances, 
MP is not totally absent in a healthy individual, and optical density levels of MP below 
0.2 are extremely rare.12,13 Macular pigment is predominantly located in the 
photoreceptor axon layer and the inner plexiform layer of the macula,14 where it 
probably plays a role in photoreceptor protection by neutralizing free oxygen radicals 
and by absorbing potentially phototoxic, high-energetic blue light (400–530 nm).15,16 
 The macula of SLS patients lacks the normal dark yellowish appearance, a 
feature that had not been appreciated fully previously.2,3 This is probably because the 
phenomenon easily could be overlooked by the considerable number of bright, glistening 
crystals at the macula. To decide whether an altered distribution or concentration of 
MP could be responsible for the changed macular shades, previous ophthalmologic 
studies on SLS patients with fundus autofluorescence (FAF) and spectral fundus 
reflectometry were expanded to compare the levels of lutein and zeaxanthin in the 
eyes of SLS patients with those of healthy controls.17,18 
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Patients and Methods 
A cross-sectional, observational study was performed on patients from an earlier 
investigated population with clinically and genetically proven SLS,3 treated at the 
Departments of Ophthalmology and Pediatric Neurology, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands. The study was performed in 
accordance with the tenets of the Declaration of Helsinki (1983 revision). Local ethics 
committee approval was obtained, and informed consent to participate in this study 
was acquired from all subjects. Because of the mental retardation in SLS, informed 
consent for study participation also was received from the patient’s parents or legal 
guardian. 
 Limited cognitive capacities, photophobia, and inability for stable fixation resulting 
from spasticity complicated the clinical examinations, especially the acquisition of 
autofluorescence images and fundus reflectometry. Therefore, data using these 
methods could be obtained only in a subset of patients. The diagnosis of SLS was 
proven in all patients by deficient FALDH activity in leukocytes or cultured skin 
fibroblasts and mutation analysis of the FALDH gene.19 
 Besides a general ophthalmic examination that included best-corrected visual 
acuity, slit-lamp biomicroscopy, binocular ophthalmoscopy, digital color fundus 
photographs (Imagenet; Topcon Corporation, Tokyo, Japan) also were obtained. In 
addition, OCT scans (transmacular line scans) and FAF images were performed by a 
hybrid OCT– confocal scanning laser ophthalmoscope (Spectralis; Heidelberg 
Engineering, Heidelberg, Germany). 
 The protocol to derive FAF images was applied as described elsewhere.20 In the 
presence of MP, decreased levels of autofluorescence usually are visible in the 
macular area because of the blue light-absorbing properties of MP. To quantify MP, a 
2-wavelength method (blue λ, ~460 nm; green λ, ~530 nm) should be used, which 
is technically impossible with Spectralis; therefore, only a qualitative estimation on the 
presence of MP was realizable in this study arm. 
 To show a possible loss of MP objectively, the optical density of macular pigment 
(MPOD) by fundus reflectance spectroscopy using the Macular Pigment Reflectometer 
(MPR) was measured.21,22 Details of this setup and the spectral analysis used are 
described by van de Kraats et al17 and by Berendschot et al23 and Berendschot and 
van Norren,24 respectively. To determine MPOD values at different eccentricities, the 
MPR was modified by adding 5 fixation points at 1, 2, 4, 6, and 8 degrees next to the 
central measurement field of 1 degree.18,25 Because of a fixed location of the eccentric 
fixation points in the MPR, they are always presented on the right side of the central 
white light (i.e., temporally for the right eye and nasally for the left eye). A single 
measurement on the MPR takes 1 second. The mean of 5 measurements was used. 
For comparison with normals, MPOD spatial profiles were taken from van de Kraats 
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et al,18 who measured 23 healthy subjects (mean age ± standard deviation, 24.3±2.7 
years) at 0, 1, 2, 4, and 8 degrees using a similar device for determination of MPOD. 
Results 
Twenty-eight eyes of 14 patients with SLS (7 male, 7 female; mean age ± standard 
deviation, 20±9 years) were included. Patient demographics, best-corrected visual 
acuity, FAF data, and MPOD measurements are summarized in Table 1. All patients 
showed the characteristic crystalline macular dystrophy on ophthalmoscopy and 
OCT. In contrast to normal fundus appearance, a relatively homogenous orange 
background reflectance was observed beneath the area of the obvious glistening 
white crystals (Figure 1). 
Confocal Fundus Autoﬂuorescence Imaging 
Fundus autofluorescence images were obtained in 9 eyes of 5 patients with a mean 
age ± standard deviation of 23.2±9.1 years and revealed important differences as 
compared with 20 eyes of 10 healthy controls with a mean age ± standard deviation 
of 24±3 years (Figure 2). 
 In all patients, the typical FAF attenuation in the fovea seen in healthy eyes was 
absent. Instead, the background FAF as seen in the periphery was continued within 
the macular region. In addition, focal FAF increase was observed at the foveal center 
in 7 of 9 eyes examined. Occasionally, spots of decreased FAF were observed 
perifoveally, which were not co-located with intraretinal crystals or pseudocysts. No 
FAF abnormalities were discerned outside the macular region.
Fundus Reﬂectance Spectroscopy 
Fundus reflectometry was performed successfully with central fixation in 19 eyes of 
10 patients (mean age ± standard deviation, 17.4±10.5 years; median, 16.5 years; 
range, 5–38 years). Although the mean age of SLS patients differed significantly from 
the mean age of the control subjects for MPR measurements (mean age ± standard 
deviation, 24.2±2.7 years; median, 23.9 years; range, 20 –32 years; P = 0.005), the 
data comparison was considered appropriate. The small but significant age 
difference between cases and controls is unlikely to have an impact on MP density, 
because the relationship between MPOD and age, if any, is marginal.26 Furthermore, 
MP also has been perceived in otherwise healthy premature infants and children.9,27 
 Peripheral fixation proved to be difficult for these subjects, resulting in fewer 
peripheral data. The spatial profile of MPOD from SLS patients showed very low values 
at all eccentricities and lacked the central peak present in healthy eyes (Figure 3). 
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Figure 1  Fundus appearance of the macula in Sjögren-Larsson syndrome. Color 
fundus photographs of (A) a patient with Sjögren-Larsson syndrome and (B) a normal 
control. The brightness of the macular background is relatively homogenous in the 
patient, whereas a considerable central darkening resulting from macular pigment is 
present in the healthy control. Note the large number of intraretinal crystals in the 
Sjögren-Larsson syndrome patient. 
Figure 2  Fundus autofluorescence (FAF) characteristics in Sjögren-Larsson syndrome. 
Fundus autofluorescence sample images and profiles of mean (error bars indicate 
standard deviation of mean) in (A) patients with Sjögren-Larsson syndrome and (B) 
healthy, age-matched controls. Study subjects show an autofluorescence maximum 
within 1-degree eccentricity, which is roughly 25% more than the peripheral levels. Instead, 
healthy individuals show central attenuation of autofluorescence of approximately 50% 
and highest values in the periphery. AU = arbitrary units.
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Mean MPOD values at 0, 4, 6, and 8 degrees of eccentricity were always less than 
0.13. At the fovea, mean MPOD (mean ± standard deviation, 0.10±0.07) was 
decreased significantly compared with that of control subjects (mean ± standard 
deviation, 0.69±0.17; P<0.001, Student t test). Spectral subanalysis revealed that MP 
in SLS almost solely constituted of lutein and that zeaxanthin was virtually absent. 
Average foveal zeaxanthin fraction (zeaxanthin/lutein plus zeaxanthin) was 0.14, 
compared with 0.24 in healthy controls (P<0.001, Student t test). 
Discussion 
This article reports on the lack of macular pigment in patients with juvenile, crystalline 
macular dystrophy resulting from SLS. This was indicated by the absent yellowish 
reflex of macular pigment on fundoscopy and the missing macular FAF attenuation in 
SLS patients. Quantitative analysis by MPR revealed virtually complete absence of 
carotenoids, especially zeaxanthin, within the central retina of SLS patients. Recently, 
Figure 3  Graph showing macular pigment optical density measurements in Sjögren- 
Larsson syndrome (SLS). Macular pigment optical density (MPOD) is expressed on 
the vertical axis, against foveal eccentricity in degrees on the horizontal axis. Data of 
patients with SLS, obtained from 9 right eyes (OD) and 10 left eyes (OS; see Table 1), 
had significantly lower foveal MPOD values compared with healthy controls (P<0.001, 
Student t test). Error bars indicate the standard deviation. The line is drawn as a guide 
to the eye. At 1 degree, only one measurement was available in the SLS cohort, and 
at 2 degrees, only two measurements were available in the SLS cohort. Therefore, 
no error bars were placed here.
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acquired partial MP loss has been reported in patients with macular telangiectasia 
type 225; however, the authors are not aware of any earlier description of virtually 
complete absence of MP resulting from a genetic disorder. Normally the MPOD 
peaks at, or near, the foveal center and then decreases rapidly with eccentricity.5,7 
The shape of MPOD distribution in SLS, however, seems to be flat over the central 8 
degrees of eccentricity, lacking the well-known profile of MPOD observed in healthy 
subjects. 
 The findings of this study correspond with the ophthalmic symptoms observed 
in SLS patients. Short-wavelength light, which is filtered by MP in large part, has been 
shown to induce more intraocular stray light than light of longer wavelengths.28 
Reduction or absence of MP therefore may lead to increased intraretinal straylight 
and hence, photophobia. Furthermore, it has been demonstrated that the amount of 
MP, clearly reduces the deleterious effects of glare, an effect that was supposed to 
be based mainly on filtering.29 In addition, the central levels of MP seem to contribute 
to improved visual performance, mainly in the short-wavelength spectrum (Snodderly 
DM, et al. Invest Ophthalmol Vis Sci:E-Abstract 2009;50:1702). Besides retinal 
thinning and pseudocyst formation, the absence of macular pigment together with 
the presence of highly refractive intraretinal crystals may induce increased amounts 
of stray light at the fovea, and hence, may play an important role in the ophthalmic 
symptoms of SLS patients, such as reduced visual acuity and photophobia. The lack 
of MP-related protection from high-energetic photons also may add to the 
degenerative processes, leading to macular thinning and pseudocyst formation. 
 Optical coherence tomography imaging in SLS patients displayed intraretinal 
crystals within the central 8 degrees of foveal eccentricity.3 These crystalline deposits 
seemed to be located mainly in the ganglion cell layers and inner plexiform layer. 
Thus far, the biochemical nature of the glistening dots remains unknown; however, 
the site of their location on OCT corresponds with the histologic position of MP in 
the normal retina.14 This co-localization suggests a relationship of the formation of 
intraretinal crystals and the absence of MP. 
 The human body is unable to synthesize any carotenoids, and therefore is 
completely dependent on dietary carotenoids, including lutein and zeaxanthin. Lutein 
and zeaxanthin are absorbed by intestinal mucosal cells and incorporated into 
chylomicrons that are secreted into the lymphatic system and subsequently enter the 
circulation. Hepatic cells incorporate the carotenoids from the chylomicrons into 
lipoproteins that facilitate further transport of the carotenoids to the various body 
tissues. Transportation, distribution, and uptake of plasma lipoproteins are regulated 
by apolipoproteins that are produced by many organs, including the liver. Apolipo-
protein-E, which is produced in the eye by Müller cells and in the retinal pigment 
epithelium (RPE), is known to play a part in lipid transportation and binding of 
lipoproteins to target sites within the central nervous system and in the targeted 
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uptake of the lipoproteins carrying lutein and zeaxanthin within the retina. Interestingly, 
Müller cell degeneration seemed to be involved in the development of the juvenile 
maculopathy in SLS.3 Furthermore, normal plasma levels of lutein and zeaxanthin 
were found in SLS patients (Willemsen MAAP, doctoral thesis, Radboud University 
Nijmegen, Faculty of Medicine, Nijmegen, The Netherlands, 2001; available at: http://
ubn.ruhosting.nl/dissertatie/dissertaties_1J2001.html; accessed September 6, 2009). 
Therefore, a disturbed retinal MP metabolism, presumably located within the retinal 
Müller cells, seems to be the most probable reason for MP deficiency in SLS. The 
characteristic crystals seen in patients with SLS typically develop in the first 2 years 
of life. The metabolic pathway, in which the FALDH deficiency contributes to the 
appearance of these deposits, is yet undiscovered. The location and time of 
manifestation, together with absence of MP, suggests that the glistening dots are 
spin-offs of a disturbance in MP metabolism. 
 The macula has a very active lipid metabolism that could be affected by FALDH 
deficiency in many different ways. A literature search revealed only a single histo-
pathological case report, describing the postmortem retinal changes in a 23-year old 
SLS patient.30 At the level of the macular retinal pigment epithelium, an increased 
amount of lipofuscin granules and a significant decrease in the amount of melanin 
and melanolipofuscin granules was observed. The lack of MP probably leads to 
uncontrolled oxidative stress, which may cause photoreceptor damage and accumulation 
of waste products indigestible for the RPE. Furthermore, FALDH deficiency itself 
results in the accumulation of many fatty alcohols and fatty aldehydes that in vitro 
also can react with phosphatidylethanolamine, forming lipofuscin like substances.31 
 The aforementioned pathophysiological processes are very likely to cause the 
focally increased FAF in most of the SLS patients examined here. Recently, 2 
additional cases of with similar changes of foveal FAF have been described.32 The 
authors concluded that the glistening dots may be the source of increased FAF in 
SLS. However, in the current series of 9 eyes, spots of increased FAF were not 
co-located with the crystals seen on fundus photography in any case. In contrast, 
increased FAF occurred mostly at locations where no crystals were visible. Therefore, 
foveal hyperfluorescence in SLS most likely originates from increased levels of retinal 
and subretinal fluorophores, that is, lipofuscin and its derivates. 
 In SLS, the presumed Müller cell degeneration with subsequent absence of MP 
leads to increased photooxidative stress. The formation of highly active free oxygen 
radicals and oxidation of lipofuscin causes damage to the retinal pigment epithelium 
and eventually photoreceptor degeneration. This additionally may lead to increased 
accumulation of lipofuscin and retinal pigment epithelium degeneration, reflected by 
focally increased and decreased FAF in SLS, respectively. 
 Dietary lutein supplementation, especially for the purpose of age-related macular 
degeneration prevention, has been investigated extensively in past decades. The 
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macular response to increased lutein and zeaxanthin serum concentrations is not 
similar in all patients, and the increase of MPOD varies strongly.8,33,34 The role of MP 
increase in late age-related macular degeneration prevention remains controversial. 
It is also uncertain whether supplementation of carotenoids is beneficial in SLS 
patients. First, blood levels of carotenoids are supposed to be normal, as found by 
Willemsen (Willemsen MAAP, doctoral thesis, 2001. Available at: http://ubn.ruhosting.
nl/dissertatie/dissertaties_ 1J2001.html; accessed September 6, 2009) and therefore 
whether uptake in the retina is appropriate is uncertain because the SLS patients 
measured herein displayed very low levels of MP despite normal carotenoid blood 
levels. Second, highly concentrated carotenoids may undergo oxidation into so-called 
carotenoid derived aldehydes, which are highly reactive and can cause significant 
oxidative stress that is comparable with the oxidative stress from lipid peroxidation 
products.35 Therefore, a risk for additional retinal damage resulting from carotenoid 
supplementation in SLS patients cannot be excluded. 
 In conclusion, the juvenile, crystalline maculopathy in SLS shows a significant 
lack of central macular pigment compared with healthy eyes. This may be caused by 
a reduced carotenoid accumulation in the macula. Additional focal changes of 
fundus autofluorescence point to increased foveal lipofuscin content and parafoveal 
atrophy of the retinal pigment epithelium. This may be the result of increased pho-
to-oxidation and cellular toxicity as a consequence of macular pigment deficiency. 
Based on the complex pathobiochemistry in SLS, a complementary diet with 
carotenoids may be harmful. 
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Abstract
Patients with the Sjögren-Larsson syndrome (SLS) suffer from a generalized 
ichthyosiform hyperkeratosis with a striking pruritic character resulting in excoriations 
and scaling. We performed a randomized double-blind, placebo-controlled trial in 
crossover design to assess the effect of blocking leukotrienes synthesis with zileuton 
on general skin condition and pruritus in ten SLS patients. Erythema, desquamation, 
lichenification and excoriations were scored each visit complemented with a Physician 
Global Assessment (PGA) of the skin. Primary outcome measures were changes in 
scores during treatment with zileuton. Also, self-reported visual analogue scales 
(VAS) for pruritus and excoriations were studied. Individual data analysis showed a 
consistent and convincing response to treatment in one patient (success rate 
approximately 10%). Therefore, we suggest a therapeutic trial with zileuton during 4-6 
weeks in all patients with SLS ≥5 years old with severe pruritus. If no clear beneficial 
response is noted during this period, treatment should be discontinued. 
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Introduction
Sjögren-Larsson syndrome (SLS) is an autosomal recessive neurometabolic disorder 
characterized by ichthyosis, spastic di- or tetraplegia and intellectual disability. Mostly, 
the ichthyosis is congenital or develops early in life. The neonatal skin has an erythrodermic 
appearance gradually evolving into a generalized ichthyosiform hyperkeratosis during 
infancy. Incidentally, SLS presents with a collodion membrane.1 Skin lesions follow a 
generalized distribution pattern being more prominent in the flexural areas, neck and 
lower abdomen sparing the central face. The hyperkeratosis thickens the skin, 
resembling lichenification, and produces a yellowish dark-brown color (Figure 1). 
Ichthyosis in SLS differs from other cornification disorders by the pruritic character 
resulting in excoriations and scaling.
SLS is caused by mutations in the ALDH3A2 gene located on chromosome 17 which 
results in a deficiency of microsomal fatty aldehyde dehydrogenase (FALDH) causing 
a disturbed  bodily lipid metabolism.2,3 The lipid metabolism plays an important part 
in the normal formation of the water barrier in the stratum corneum. In SLS patients, 
lamellar bodies, synthesized in the stratum granulosum and normally containing 
essential precursor membranes, are misshapen and empty. This results in defective 
membrane formation and a leaky water barrier. To restore function, the skin reacts by 
hyperkeratosis resulting in ichthyosis.4-6 
Figure 1  Ichthyosis in SLS. The hyperkeratosis thickens the skin, resembling 
 lichenification, and produces a yellowish dark-brown color.
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 FALDH is important for formation and excretion of lamellar bodies. Deficiency 
leads to several disrupted lipid pathways, but it is unclear which specific pathways 
are involved in the SLS dermatological phenotype. Pruritus may, however, have 
another pathophysiological origin. Previously, we showed an association between 
pruritus and elevation of pro-inflammatory leukotriene B4 (LTB4), which is also 
FALDH-dependent for its breakdown. This association was later confirmed in 
experimental mice studies.7,8 In allergic skin inflammation (e.g. atopic dermatitis, 
psoriasis etc.), LTB4 plays a crucial part in the inflammatory response.9 In SLS, 
elevation of dermal LTB4, by either increased production or defective breakdown or 
a combination of both, probably plays an important role in its dermatological 
phenotype. Zileuton is an active oral inhibitor of 5-lipoxygenase, an enzyme forming 
leukotrienes from arachidonic acid. Blocking this pathway results in reduced 
formation of leukotrienes, including LTB4.
 Before, we studied zileuton treatment in 5 SLS patients (non-placebo controlled 
study).10,11 Treatment reduced urinary concentrations of LTB4 and 20-OH-LTB4, 
indicating in vivo effectiveness. Clinically, beneficial effects on pruritus and general 
well-being were described. To further investigate the effects of zileuton on the skin, 
we performed the current randomized controlled trial (RCT).
Materials and methods
Study design and participants
We used a crossover design in this single-center RCT, resulting in each participant 
being its own control. Approval of the Regional Committee on Research involving 
Human Subjects Arnhem-Nijmegen was obtained. From June 1st 2012 to November 1st 
2012, patients were enrolled at the Radboud university medical center (Radboudumc) in 
Nijmegen, the Netherlands. Because of substantial intellectual disability in all patients, 
informed consent was obtained from their parents. 
 Patients with genetically and biochemically confirmed Sjögren-Larsson syndrome, 
aged 5-60 years were included in the study. Exclusion criteria were (1) hepatic failure; 
(2) usage of theophylline, cumarin derivates, beta-blockers, terfenadine and/or 
pimozide; (3) alcohol consumption or smoking; and (4) pregnancy or lactation. All 
patients continued current dermatological treatment (‘daily practice’) during the study 
period. 
Treatment
Zileuton is US FDA approved for chronic treatment of asthma in patients ≥ 12 years. 
Zileuton is not approved by the European Medicines Agency (EMA) or the Dutch 
Medicines Evaluation Board. Inhibition of LTB4 biosynthesis in whole blood is directly 
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related to zileuton plasma concentration.12,13 Since we expected the same mechanism 
of action to be responsible for reduction of pruritus in SLS, our aim was to achieve 
similar exposure to zileuton as in asthmatic patients. Zileuton pharmacokinetics in 
asthmatic adult patients are comparable to those in healthy volunteers.13-15 Also, 
pharmacokinetics of zileuton in children (9-12 years) are comparable to those in 
adults after the adjustment of dose for body weight or body surface area.13 
For patients ≥ 12 years of age, dosages as currently approved for the treatment of 
asthma (zileuton 600mg quater in die; qid) were used.  To determine dosages for 
younger patients, the guidance for pediatric dosing was used.16 Zyflo® 600mg tablets 
were provided by the manufacturer (Cornerstone Therapeutics Inc., US). Placebo or 
zileuton capsules with identical appearances were prepared in the hospital pharmacy.
Randomization and allocation to treatment
All patients received treatment with either zileuton or placebo in two periods of 
8 weeks, separated by a wash-out period of 4 weeks. Based upon the pharmaco-
kinetics and pharmacodynamics of zileuton, these treatment periods were considered 
long enough to demonstrate clinical effects.17 A 4-week wash-out period was 
considered sufficient because of the short half-life of both zileuton (2.5h) and 
leukotrienes.18 Treatment order was randomly assigned and randomization was 
performed by the hospital pharmacy. Assessors and patients were blinded to 
assignment of treatment.
Data collection
Visits were scheduled for all patients at t=0 (start first treatment period), t=8 weeks 
(stop first treatment period), t=12 weeks (stop wash-out period and start second 
treatment period), t=20 weeks (stop second treatment period) and t=24 weeks (stop 
second wash-out period). At t=0, baseline measurements were performed by two 
assessors (M.S. & J.F.) producing one mutual assessment for all patients. All 
subsequent measurements were performed by one assessor (J.F.). 
 During all visits, structured dermatological assessment was performed using the 
Sjögren-Larsson Severity Index (SLaSI), specifically designed for this study using 
items from the Psoriasis Area and Severity Index (PASI).19 The SLaSI outcomes 
erythema, desquamation, lichenification and excoriations were scored separately on 
a 5-points severity scale (0-4 with 4 being most severe) assessing four different areas 
of the body (head, trunk, upper and lower extremities) each visit. This was done to 
improve detection of partial effects and differs from PASI. For each SLaSI outcome, 
the arithmetic mean of all body areas scored was calculated for each patient at each 
visit leading to ‘SLaSI mean scores’. To measure global changes, the Physician 
Global Assessment (PGA) tool (range 0-5; 5 being most severe) was performed 
during all visits.20
88
 Urine samples were collected at each visit and stored at -80 °C within maximally 
6 hours after collection.
 Primary caregivers weekly scored pruritus and excoriations in all patients during 
the entire study period using a Visual Analog Scale (VAS) instrument consisting of 
100-mm horizontal lines marked with ‘no pruritus’ or ‘no excoriations’ on the left and 
‘severe pruritus’ and ‘severe excoriations’ on the right. The scoring forms were weekly 
sent to the primary investigator. 
Primary outcome measures (POM)
POM were the differences in SLaSI mean scores and PGA scores before and after 
treatment with zileuton or placebo. 
Secondary outcome measures (SOM)
SOM were individual changes in VAS scores. To investigate zileuton’s safety profile in 
SLS, adverse events were reported and serum aminotransferases were determined 
at each hospital visit.
Statistical analysis
Primary analysis involved studying changes in SLaSI mean scores and PGA scores 
during treatment. Data were analyzed for the two treatment periods (t=0-8 weeks 
and t=12-20 weeks) combined and separately using paired samples t-tests, 
comparing: 1) the scores at the start of the treatment period with those at the end of 
the treatment period (treatment); 2) the scores at the end of the treatment period with 
those at the end of the wash-out period (wash-out); and 3) the scores at the start of 
the treatment period with those at the end of the wash-out period (treatment + 
wash-out). Comparison 2 (wash-out) was done to detect reversal of potential 
beneficial effects from zileuton after discontinuation of treatment. Comparison 3 
(treatment + wash-out) was added post-hoc to check for potentially longer-lasting 
therapeutic effects of zileuton after treatment discontinuation. To detect potential bias 
by seasonal influences on skin condition, the mean changes in scores from the 
patients receiving treatment with zileuton were compared with those from the placebo 
group in the same treatment period using independent samples t-tests. To assess 
intra-observer variability, individual SLaSI mean scores and PGA scores from patients 
receiving zileuton in the second treatment period were compared between t=0, t=8 
and t=12 weeks, before they received any treatment. 
 SOM were studied by calculating individual mean VAS scores during treatment 
periods with zileuton and periods with placebo treatment for the outcomes pruritus 
and excoriations separately. Previous experience led to the assumption that only a 
minority of patients would respond to zileuton. Therefore, POM were also analyzed in 
each individual patient to detect responders. Because we analyzed SLaSI outcomes 
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separately, general PASI response definitions could not be used.21 Regarding SLaSI 
and PGA scores, we defined a positive response to zileuton as a decrease of ≥0.5 
after treatment. Based upon use in psoriasis, a positive VAS response was defined as 
a decrease of ≥20 during treatment.22 All separate outcomes scoring positive were 
given one point (maximum score 7 points). Patients scoring ≥5 points were considered 
responders.
Leukotrienes analysis
For LTB4 and 20-OH-LTB4 analysis samples were purified using anion exchange 
solid phase extraction with subsequent HPLC fractionation on a Acquity HSS T3 
column (100 x 1 mm/ dp = 1.8 µm; Waters Chromatography, Etten-Leur The 
Netherlands). Relevant fractions were measured using an enzyme immunoassay 
(Leukotriene B4 Express EIA Kit, Cayman Chemical Company nr 10009292, USA and 
standard for 20-OH-LTB4 from the same company nr 20190). Reference values for 
age matched healthy controls were determined in house. Total procedure was 
validated by performing recovery experiments for LTB4 and 20-OH-LTB4 which gave 
satisfactory results. 
Results
Eighteen patients were assessed for eligibility. Eight patients did not participate 
because of logistic difficulties (too many study visits, travel distance etc.). Included 
patients were randomized in one of two treatment arms. Patient characteristics are 
given in Table 1. Three patients participated in earlier zileuton studies using the same 
dosages as given in this study, but discontinued treatment afterwards because of 
supposed treatment failure. All patients completed the current study.
Primary outcomes measures (POM)
Results of analyses on the POM are presented in Table 2 by mean changes in scores 
(plus 95% confidence intervals (95%CI)) for the two treatment periods combined and 
separate. In the combined analysis, a treatment effect was only seen for the PGA 
scores, which improved on average by 0.7 (95%CI: 0.1-1.3) during treatment with 
zileuton. When analyzing the two treatment periods separately, treatment effects of 
1.0 (0.1-1.8) and 1.2 (0.2-2.2) were seen for the SLaSI outcome desquamation and the 
PGA, respectively, both in the second period and both largely maintained during 
wash-out period. Thus, a reversal of beneficial effects from zileuton after discontinu-
ation of treatment could not be detected. Simultaneously, the placebo group showed 
no effects for desquamation and PGA, thereby excluding seasonal influences upon 
these scores. 
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 In contrast, the placebo group scored better at the second period for erythema 
and excoriation, while they did much worse during the ensuing wash-out period. In 
the first period, the treatment group scored slightly better for excoriations, but worse 
again at the end of the wash-out period. The severity of desquamation seemed to 
increase during the first treatment and wash-out periods for both the zileuton-treated 
and placebo group. All other scores did not change substantially from t=0 to t=8 and 
t=12 weeks in the placebo group in the first treatment period, indicating limited 
intra-observer and seasonal variability.   
Secondary outcomes measures (SOM)
due to a logistical error, no scoring forms were collected during t=9-11 weeks. During 
the other periods, 181/210 (86%) scoring forms were returned. When treated with 
zileuton, none of the patients missed more than 2 forms. Large intra-individual 
variability in scores was seen in subsequent study weeks in some patients. Substantial 
decreases in mean VAS scores were only detected in one patient (Table 3). 
Individual responders
one patient met our criteria for ‘responder’ with a score of 6 out of 7 (Table 4). 
Subsequent retrospective analysis of the medical records from all patients showed 
that for this patient only, the parents reported a tremendous improvement of the 
clinical condition (especially regarding pruritus) in the period zileuton was 
administered. In the placebo phase, they reported to have seen no relevant effects, 
while they reported a complete setback within days after discontinuation of zileuton 
at the wash-out visit. 
Leukotrienes analysis
Urinary samples were collected for all patients during nearly all visits (except for 
patient 9 at visit T=12). Measurement of baseline concentrations of LTB4 and 
20-OH-LTB4 however failed to detect the expected differences in LTB4 and 
20-OH-LTB4 excretion between SLS patients and healthy controls due to as yet 
unknown reasons. We therefore could not reliably use urine leukotriene measurements 
in this study.
Adverse events
No adverse events related to the study drug were observed. Patient 6 suffered from 
a urinary tract infection treated with co-trimoxazole (during placebo treatment). 
Patient 9 had chickenpox during her visit at t=24 weeks. The serum aminotransferas-
es remained within normal limits in all patients.
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Discussion
Key findings
Except for small effects on SLaSI scores for desquamation and PGA scores in the 
second treatment period, changes in mean scores were not different between the 
zileuton and placebo groups. However, one patient responded on zileuton treatment 
with substantial changes in almost every scoring item. Upon parental request, the 
patient continued zileuton and was monitored closely. Follow up (~1 year) after the 
study showed a consistent beneficial therapeutic effect. Discontinuation of treatment 
(due to a lack of zileuton supplies) led to a setback shortly after stopping zileuton, 
which was reversed upon resuming treatment. This observation of prompt and clear 
response to starting and stopping zileuton treatment corresponds to previous 
findings.11 From the patients treated previously, one other patient (female, 24 years) 
still uses zileuton (600mg qid) and reports lasting beneficial effects. It remains 
unclear, however, why only some patients respond to treatment. 
 Although genotypes in SLS differ, the corresponding clinical phenotype as well 
as degree of enzyme deficiency are usually quite homogeneous making it impossible 
to predict responders using clinical (or biochemical or genetic) decision models. 
Both responders from these two studies have different genotypes and lack residual 
FALDH activity. Nonetheless, minimal but perhaps relevant variations in concentrations 
of abnormal metabolites may still exist in patients, but cannot be detected because 
of insufficient sensitivity of biochemical assays. To improve general condition of the 
skin and pruritus, some adult patients are treated with acitretin, but adverse effects 
are frequently reported.23 In this study, no adverse events were detected and zileuton 
is considered safe for usage in SLS. This is a major advantage over the use of acitretin 
when treating pruritus in SLS patients.
Limitations
Despite state of the art study design and realization, some limitations have to be 
mentioned. Due to the small sample size, it is difficult to draw firm conclusions. However, 
it is near impossible to perform studies with larger patient groups, given that SLS is a 
rare disease. 
 LTB4 is produced by epidermal keratinocytes upon stimulation of specific 
receptors.8 Research in mice proved that orally administered zileuton has the ability 
to inhibit epidermal LTB4 production and decrease pruritus.24 However, correlations 
between zileuton dosages used in animal research and the dosages used in this study 
are unclear. 
 Use of zileuton in SLS is off-label and no formal dose finding studies have been 
performed. Dosages used were based on the treatment of asthma, in which leukotrienes 
are formed by mast cells that may have different biochemical responses to zileuton 
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than keratinocytes.25 In addition, it is possible that dosages of zileuton in SLS should 
be higher than used here to sufficiently penetrate epidermal layers or have stronger 
inhibitory effects on leukotriene formation. As the one responder had the lowest body 
weight of all patients, she received a relatively high dosage for weight (81mg/kg total 
daily dose) compared to other participants <12 years (respectively 70 and 74 mg/kg 
total daily dose). Higher dosages of zileuton may be needed to increase the number 
of responding patients. 
 Due to unsuccessful urinary leukotriene analysis, we could not confirm bio -
chemically that exposure to zileuton in this study was sufficient to decrease leukotriene 
production.
 In our previous study, however, we reported effects on urinary concentrations 
using the same dosages of zileuton for patients ≥12 years.11 Nonetheless, the correlation 
between decreasing urinary LTB4 concentrations (representing total body leukotriene 
production) and a decrease of locally formed LTB4 in keratinocytes has not yet been 
studied.
 The intellectual disability in SLS patients may result in scratching becoming habitual 
behavior. Therefore, scratching may continue although the pruritus is diminished by 
zileuton treatment, disguising potential beneficial effects.
 Data from the treatment plus wash-out period suggest prolonged beneficial 
effects of zileuton on the skin. However, the responding patient repeatedly reported 
setbacks within days after discontinuation of zileuton treatment. Consequently, we 
presume that beneficial effects of zileuton treatment, if present, will appear within days 
to weeks after treatment initiation and will disappear shortly after discontinuation.    
Conclusion
Zileuton in the currently used dosages is safe to treat pruritus in SLS. Approximately 
10% of the patients seem to respond and responders can easily be detected and will 
experience a significant improvement in quality of life. We suggest a therapeutic trial 
with zileuton during 4-6 weeks in SLS patients ≥5 years, especially when medical 
treatment for severe pruritus is warranted. If no clear beneficial response to zileuton 
is noted, treatment should be discontinued. Dose-finding with higher doses of 
zileuton in non-responders should not take place in individual patients, but would 
necessitate further research focusing on pharmacokinetic – pharmacodynamic 
relationships of zileuton in SLS patients.
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Abstract
This review article gives a state-of-the-art synopsis of current pathophysiological 
concepts in Sjögren-Larsson syndrome (SLS) mainly based upon original research 
data of the authors in one of the world’s largest clinical SLS study cohorts. Clinical 
features are discussed in order of appearance, and diagnostic tests are set out to 
guide the clinician toward the diagnosis SLS. Furthermore, current and future 
treatment strategies are discussed to render a comprehensive review of the topic. 
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Introduction and historical perspective  
of the research group 
In 1957, the Swedish physicians Sjögren and Larsson reported a cohort of 28 familial 
interrelated patients diagnosed with the clinical triad of mental retardation, spastic 
diplegia, and congenital ichthyosis following a seemingly autosomal recessive 
pattern.1 Although, in retrospect, other patients with apparently the same disorder 
had been described previously, the name Sjögren-Larsson syndrome (SLS) has 
been used since then. In succeeding decades, more patients were reported, adding 
up to a clinical picture with variable predominance, especially toward the degree of 
spasticity and ichthyosis. Additional clinical features were described, such as a distinctive 
crystalline maculopathy and impaired speech-language performance. In 1988, Rizzo 
et al. discovered that a deficient microsomal fatty aldehyde dehydrogenase (FALDH) 
underlies SLS.2 FALDH is part of the fatty alcohol nicotinamide adenine dinucleotide 
(NAD) oxidoreductase complex (FAO) and catalyzes oxidation of many different 
medium-and long-chain fatty aldehydes into fatty acids. Deficiency results in the 
accumulation of fatty aldehydes and fatty alcohols in body tissues, which is considered 
the principal causative mechanism leading to the overall clinical phenotype of SLS.3 
Besides its important role in fatty alcohol metabolism, FALDH is also involved in the 
breakdown of pro-inflammatory leukotrienes (Figure 1). Accumulation of precursor 
metabolites is thought to be particularly involved in the dermatological phenotype 
of SLS. 
 Later on, in 1996, the genetic basis of SLS was unravelled by De Laurenzi et al.4 
The FALDH gene, recently renamed ALDH3A2, is located on chromosome 17p11.2, 
consists of 11 exons, and spans about 31 kb. By now, more than 70 different mutations 
in the ALDH3A2 gene have been identified in SLS patients originating from about 120 
different families. As recently reviewed by Rizzo and Carney, mutations in SLS are 
scattered throughout the ALDH3A2 gene and are generally private mutations, 
occurring in single cases.5 Most mutations result in a complete loss of catalytic 
activity of FALDH, although there are several (missense) mutations associated with 
residual FALDH activity. For more than two decades, our Dutch research group has 
studied clinical, biochemical, and genetic aspects of SLS. During the years, we have 
extended our study cohort to > 30 genetically proven SLS patients. This clinical 
review summarizes the main study results and provides a state-of-the-art synopsis of 
current pathophysiological concepts. 
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Clinical features 
We discuss details of the main clinical features in SLS in order to guide the clinician 
toward a clinical diagnosis of SLS and to offer a framework for appropriate follow-up 
and care. 
Skin disorder 
In the majority of the patients, ichthyosis is congenital or develops very early in life. 
The neonatal skin may first have an erythrodermic appearance, gradually evolving 
into a generalized ichthyosiform hyperkeratosis during infancy. Ichthyosis follows a 
generalized distribution pattern and is more prominent in the flexural areas, neck, and 
lower abdomen. The central face is often spared. Hyperkeratosis thickens the skin, 
resembling lichenification, and produces a yellowish, dark-brown color (Figure 2). 
Ichthyosis in SLS is different from other cornification disorders by the striking pruritic 
character, resulting in excoriations and more scaling. It is the result of a defective lipid 
barrier in the stratum corneum of the skin. Seemingly, FALDH plays an important role 
in epidermal functioning, and its deficiency results in a leaky water barrier causing 
ichthyosis.6 Besides the skin, other ectodermic structures are not affected, though 
most patients from our cohort have relative heat intolerance probably due to 
hypohydrosis. 
Figure 1  LTB4 degradation as an example of one of the pathways disturbed in fatty 
aldehyde dehydrogenase (FALDH) deficiency.
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Neurological disorder
The motor problem in SLS is summarized as bilateral spastic paresis involving the 
legs more than the arms. In 2008, we performed a cross-sectional study of motor 
performance and everyday functioning in 17 of our patients.7 In doing so, we found 
that none of the adolescent participants was able to walk without restrictions, and 
most patients with SLS use a wheelchair to move around outdoors. In five patients, 
parents reported that their child had been able to walk with or without support but gait 
had deteriorated gradually over time. There seems to be a limit in motor performance 
and everyday functioning, with most participants reaching a developmental age of 
maximally 12 years. Later, in adolescence, neurological features stabilize, and the 
clinical picture behaves rather like stationary cerebral palsy than the progressive 
deterioration often seen in other neurometabolic disorders. 
 Most of the patients suffer from moderate cognitive impairment and typically 
reach a developmental age of 5–6 years. In our study cohort, some patients reached 
a certain level of independence, self-care, and mobility in an adapted environment, 
though most of them had limited social interaction with peers and their participation 
was restricted. In assessments of cognitive capacity of adult patients (n=6) from our 
cohort, history—including well-documented school performances of many other 
patients, as well as the available data in the literature—all point to stable intellectual 
capacities in SLS without any loss of acquired cognitive abilities during at least the 
Figure 2  Skin. Hyperkeratotic thickening of the skin, with a yellowish, dark-brown color.
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first three to four decades of life.8 Epileptic seizures are encountered in the minority 
of patients with SLS; they do not dominate the clinical picture and are generally easily 
treatable with antiepileptic monotherapy. 
 Almost all patients suffer from a mild-to-moderate (pseudobulbar) dysarthria, 
which influences speech audibility and, together with a delay in language 
development, aggravates their already poor communicative functioning in daily life. 
Although most patients learn to talk, some are left with complete anarthria. Oral facial 
motor functioning is impaired, and most SLS patients have poor upper facial 
musculature functioning. Remarkably, severe dysphagia was not encountered in 
these patients, and accordingly, none depended on gastric tube feeding in daily life. 
The degree of cognitive impairment relates to the degree of language impairment, as 
was demonstrated in our previous study.8 No clear relationship between motor 
functioning (spasticity) and dysarthria or cognitive development was observed in our 
study series. Thus, given the variability in cognitive and speech–language development 
within different levels of motor impairment, spasticity is not likely the limiting factor in 
cognitive and speech–language development in these patients. 
 Magnetic resonance imaging (MRI) in SLS shows normal gross anatomy of the 
brain, with periventricular white matter abnormalities ranging from (very) mild to 
severely increased signal intensities on T2–weigthed images (Figure 3). These 
abnormalities occur in the first 2 or 3 years of life and stay stable thereafter. Myelination 
is generally slightly delayed, and most patients show a discrete permanent deficit in 
myelination. Only at ages >10 years may slight cerebral atrophy be seen. 
 Proton magnetic resonance spectroscopy (H-MRS) shows moderate changes of 
the known metabolites (normal N-acetylaspartate and glutamine/glutamate; increased 
choline, creatine and myoinositol), reflecting white matter gliosis without significant 
axonal damage or loss. In patients from the age of 1 or 2 years onward, H-MRS 
shows highly characteristic, almost pathognomonic, abnormal resonances at 1.3 and 
0.8–0.9 ppm in cerebral white matter but not in grey matter spectra, reflecting lipid 
accumulation (Figure 4).9 To date, the exact nature of the accumulating lipids is 
unknown. Over the years, we have seen some very rare exceptions to the rules, i.e., 
patients with very severe MRI signal changes or with hardly any lipid peak on H-MRS. 
Nevertheless, we think that combined MRI and H-MRS data in patients >2 years 
almost always are highly suggestive, if not pathognomonic, for SLS, especially in the 
context of a patient with a neurocutaneous disorder. 
Ophthalmological abnormalities
In early infancy, a peculiar crystalline macular dystrophy develops in patients with 
SLS. Clinically, this maculopathy is accompanied by decreased visual acuity of a 
certain degree and by photophobia. Ophthalmoscopy reveals perifoveal crystalline 
deposits located in the inner retinal layers, which may reflect accumulation of 
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pathological lipids (Figure 5). In recent years, we extended our studies on this macular 
dystrophy by using optical coherence tomography (OCT). This technique, which 
allows depiction of single retinal layers, showed a clear change in macular morphology 
and reflectivity compared with healthy eyes (Figure 6).10 By OCT, we were able to 
localize crystals within the perimacular ganglion cell layer and the inner plexiform 
layer. Interestingly, we detected a cystic foveal degeneration by OCT in the majority of 
patients with SLS, varying from multiple microcysts to cystic foveal atrophy. In general, 
patients who were severely affected on OCT also showed intense changes on 
previously performed cerebral MRS. 
Figure 3  Magnetic Resonance Imaging (MRI) in a 5 year old girl with SLS. Severe 
periventricular signal changes on T2 (top) and T2-FLAIR (bottom) images.
110
 Furthermore, we studied the macula in these patients by using fundus autofluo-
rescence and the macula pigment reflectometer. These examinations revealed 
significantly reduced levels of central retinal macular pigment, indicating a lack of 
retinal carotenoids.11 The cystic foveal degeneration together with the lack of macular 
pigment are presumably a sign of retinal Müller cell degeneration in patients with 
SLS. The changes observed with the macular pathology in SLS correlates well with 
the generally observed clinical features of reduced visual acuity and photophobia. 
Preterm birth
We were the first to recognize that preterm birth is a clinical hallmark, in fact the very 
first sign, of SLS. In out cohort, we have encountered preterm birth in 18 of 25 (72 %) 
of all patients with exactly known gestational ages at birth. In this series, we calculated 
a mean gestational age at birth of 35.6 [standard deviation (SD) 2.1] weeks. Only 
three cases were born < 33 weeks or > 37.5 weeks, namely 28 weeks (n=1) and 38 
weeks (n=2). In many case descriptions in the literature, preterm birth is also reported. 
Apparently, a fetus with SLS induces its own (preterm) birth, e.g., by excessive urinary 
Figure 4  Magnetic resonance spectroscopy (MRS) (3 Tesla, short echo time 30 ms) 
in a 39-year-old man with Sjögren-Larsson syndrome (SLS). 
Normal spectrum of grey matter (top). High lipid peak (*) in normal-appearing white matter occipitally 
(bottom). NAA N-acetyl aspartate, Cr creatine, Cho choline, Ins myoinositol
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excretion of highly active lipids (such as leukotrienes) in amniotic fluids, thus triggering 
labor through inflammatory responses.
Other signs & symptoms
In contrast to what has been reported in some cases in the literature, we could not 
confirm that the following features are part of the phenotype in SLS: microcephaly, 
short stature, peripheral neuropathy, dental enamel hypoplasia and widely spaced 
teeth, and hypertelorism.
Figure 5  Fundus. Representative color fundus photograph of juvenile maculopathy 
in Sjögren-Larsson syndrome. Note the huge amount of yellowish-white glistening 
dots around the central macula.
Figure 6  Optical Coherence Tomography (OCT). Trans-foveal OCT scan of a patient 
with Sjögren-Larsson syndrome. Note the large central pseudocyst with interruption 
of the photoreceptor layer. Glistening white crystals appear as dark, high-reflective 
dots within the nerve fibers and the inner and outer plexiform layers of the retina
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Diagnostics 
Clinical diagnosis 
Though the classical description of its most prominent features seems to make SLS 
easy to diagnose, its phenotype can be variable and develops following a typical age 
dependent pattern. The latter can make diagnosing SLS difficult, especially in young 
children. We therefore categorize the gradual development of the complete SLS 
phenotype into different age-dependent phases. 
 Preterm birth and the typical congenital erythrodermic skin or ichthyosis are the 
first symptoms of SLS. Infants presenting in this manner do not yet exhibit cognitive 
or motor abnormalities, and the typical crystalline macular dystrophy is lacking. 
Therefore, SLS is generally not suspected clinically in this very early phase. During 
early childhood (1–2 years of age) mental and motor retardation gradually become 
clear and should be followed up by cerebral imaging studies. Typical MRI and H-MRS 
abnormalities, as well as crystalline maculopathy, may be absent, and normal 
radiologic and ocular findings thus absolutely do not exclude SLS at this stage. Later 
on in childhood (from 3 years of age), the full-blown phenotype of SLS with the 
classical triad of ichthyosis, spasticity, and mental retardation is present and is 
completed with the typical findings during ophthalmological and MRI/H-MRS studies. 
Only at this stage of the disease is a clinical diagnosis of SLS generally made. 
Genetic & biochemical diagnostics
Once the clinical suspicion of SLS has arisen, diagnosis can be confirmed by 
demonstrating the enzymatic defect and mutation analysis of the ALDH3A2 gene. 
Traditionally, and in contrast to many other inborn errors of metabolism, it is very 
difficult to prove SLS at the metabolite level in body fluids. Only concentrations of 
long-chain fatty alcohols and leukotriene B4 (LTB4) metabolites have been found 
elevated in blood and urine, respectively, but these metabolites are extremely difficult 
to measure, and routine analysis is unavailable in most dedicated laboratories for 
metabolic diseases. 
 Enzyme analysis is preferably performed in cultured skin fibroblasts and can be 
done with the use of several substrates (Table 1).
 FALDH deficiency can also be demonstrated in polymorphonuclear leukocytes 
using LTB4 as the substrate, but this assay demands fresh blood cells and is very 
complex and laborious. Only very recently did we develop a much easier and also 
highly reliable assay for FALDH enzyme activity measurements in blood cells. This is 
possible using the artificial substrate pyrenedecanal, first introduced by Keller et al.12
Sequence analysis of the coding region of the ALDH3A2 gene in patients displaying 
FALDH deficiency results in the identification of two pathogenic ALDH3A2 gene 
mutations in > 95 % of patients. Although many patients harbor unique mutations, 
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two mutations, namely, c.1297–1298delGA (leading to protein truncation at position 
435 along with amino acid substitutions at 433 and 434) and c.943 C>T (p.Pro315Ser), 
are quite commonly found and considered founder mutations in Europe. Missense 
mutations are the most frequent mutation type, followed by small exonic alterations 
(deletions or insertions) that lead to protein truncation. 
Treatment options 
Classical treatment: symptomatic
Treatment should focus on the spasticity and prevention of contracture development, 
as both can bear important effects upon patients’ daily life functioning. Physical 
therapy, as well as bracing and ergonomic support, is important, as are aids to 
stimulate spontaneous movements of the child as varied as possible. Furthermore, 
speech-language therapy when started early may play an important role in optimizing 
speech-language performance and (augmented) communication and thereby 
improve daily functioning. Daily skin care focuses on diminishing scaling and pruritus 
by life-long application of different keratolytic or urea-containing emollients. 
Table 1  Substrates for fatty aldehyde dehydrogenase (FALDH): metabolites used 
to determine FALDH enzyme activity in vitro and can be measured as biomarkers in 
different bodily fluids.
Substrate In vitro In vivo Remark Reference
Hexa- and octadecanol + (F) + (B) Rizzo et al. 2000 24
Phytol + (F) - In blood  
normal values
Van den Brink et al. 
2004 19
Omega-hydroxy-C22:0 + (F) NM Sanders et al. 2009 25
Dihydrophytal + (F) NM Kelsson et al. 1997 3
Pristanal + (F) - In blood  
normal values
Verhoeven et al. 1998 26
20-CHO-LTB4 + (L) + (U) In CSF  
normal values
Willemsen et al. 2001 17
Pyrenedecanal + (F;La) NM Artificial 
substrate
Keller et al. 2010 12
F= cultured skin fibroblasts; L= leukocytes of lymphocytes; B= blood (plasma or serum); U= urine; CSF= 
cerebrospinal fluid; LTB4= leukotriene B4; NM= not measured
a = unpublished data
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Alternative options originating from psoriasis treatment, such as the topical use of 
calcipotriol, have also been used in our patients with varying degrees of success.13 
Moreover, a review from the original Swedish cohort of SLS patients described 
favorable effects of retinoids (acitretin) taken orally, mainly upon ichthyosis.14 However, 
this was based upon single-case observations, and a placebo controlled trial has not 
yet been performed to obtain objective proof. 
Alternative treatment strategies 
In past decades, and inspired by growing insights into pathophysiological 
mechanisms, multiple treatment regimes have been postulated in the literature, often 
with disappointing results. Despite some hopeful case reports of dietary treatment in 
which long-chain fatty acids were replaced by medium-chain fatty acids in an attempt 
to decrease fatty alcohol accumulation, no biochemical or clinical improvement were 
seen in the five SLS patients treated in this way. Dietary supplementation of certain 
polyunsaturated fatty acids, the deficiency of which has been described in SLS 
patients, by using primrose oil was also unsuccessful in the same study.15 Although 
the presence of biochemical variability in terms of residual FALDH activity in different 
SLS patients urges caution, so far, dietary treatment of SLS has not been successful. 
 The accumulation of leukotrienes subsequent to FALDH-dependent deficient 
degradation is presumed to play an important part in the inflammatory reactions seen 
in the skin of SLS patients. The striking pruritus from which these patients suffer and 
which is generally not seen in other ichthyotic diseases may originate from LTB4 
accumulation. Zileuton is a drug that inhibits leukotriene formation by blocking its 
biosynthesis pathway and has proven its use in managing chronic (severe) asthma. 
We investigated the effect of zileuton treatment both clinically and biochemically 
in SLS patients. Treatment of one and five patients with zileuton during a period 
of 5 weeks and 3 months, respectively, led to a significant reduction of urinary 
concentrations of LTB4 and omegaOH-LTB4.16,17 Clinically, advantageous effects 
upon pruritus, general well-being, and the electroencephalographic background 
pattern were seen. No important side effects or complications were reported. Though 
these studies have proven a potent biochemical effect of zileuton in SLS patients, the 
potential clinical effects, especially upon pruritus, require further research. To prove 
the postulated effect of zileuton upon (some) dermatological characteristics of SLS, 
a randomized double-blinded placebo controlled trial is warranted.
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Future perspective 
Bezafibrates
Recent research indicates the involvement of FALDH in the oxidative breakdown of 
phytol.18,19 Phytol is a branched-chain fatty alcohol and compound of the chlorophyll 
molecule and therefore part of our regular diet. Its breakdown is augmented by 
FALDH in two stages of the cascade: oxidation of phytenal into phytenic acid, and 
pristanal into pristanic acid subsequently. Phytanic and pristanic acid, both fatty 
acids, act in vitro as natural ligands for the nuclear hormone receptor peroxisome 
proliferator activated receptor-α (PPAR-α). PPAR-α is a ligandactivated transcription 
factor that modulates the expression of target genes. The target genes of PPAR-α are 
involved in various aspects of lipid metabolism. PPAR-α is mostly expressed in 
tissues with high rates of fatty acid catabolism, such as liver, heart, and kidney. They 
are thought to play an important part in the pathogenesis of disease modalities such 
as hypertension and dyslipidemia. Besides the natural ligands mentioned above, 
there are several artificial ligands known to activate PPAR-α, such as bezafibrate. 
 Interestingly, recent animal studies have shown that a phytol-enriched diet 
induces FALDH activity in a PPAR-αdependent manner.20 Elevated levels of phytanic 
and pristanic acid act as natural ligands and activate PPAR-α, which modifies the 
activity of the target gene by binding to a response element. Strikingly, the ALDH3A2 
gene (responsible for modulating FALDH activity) has not yet shown to have such a 
PPAR-response element and thus the molecular–genetic explanation of the 
PPAR-α-induced FALDH up regulation remains to be elucidated. 
 Nevertheless, in 2006, Gloerich et al. investigated the in vitro capability of bezafibrate, 
acting as a artificial ligand to PPAR-α, to induce FALDH expression and activity in 
human fibroblasts of healthy controls as well as SLS patients with residual FALDH 
activity.21 They found a 1.4-fold increase in FALDH activity (measured using phytol as 
substrate) in healthy control fibroblasts after incubation with 800 µM bezafibrate for 
3 days. In fibroblasts of four different SLS patients with different mutations in the 
ALDH3A2 gene but whom all had some residual FALDH activity, in vitro treatment 
with 800 µM bezafibrate for 3 days resulted in a 2.5-and 2.8-fold increase of FALDH 
activity in two SLS patients, respectively. This represents an improvement in FALDH 
activity to 34 % and 39 % of the normal FALDH activity found in healthy controls.
 This research project proves the in vitro capability of bezafibrate to induce FALDH 
activity in controls and selected SLS patients. Based upon these results, comparable 
ALDH3A2 mutations (resulting in residual FALDH activity) in SLS patients are 
suggested as candidates for bezafibrate FALDH induction. However, residual FALDH 
activity is a strict requirement for bezafibrate to be effective and is unfortunately not 
seen in many SLS patients, which limits its potential use. Besides this limitation, 
clinical implications of bezafibrate induction in SLS still need to be elucidated. 
116
Carotenoids 
We found a virtually complete absence of retinal carotenoids in those SLS patients 
available for macular pigment examination.11 Macular pigment, consisting of the 
dietary- derived carotenoids lutein and zeaxanthin, plays an important role in 
protecting the retinal photoreceptors by neutralizing free oxygen radicals and by 
absorbing potentially phototoxic, high-energy blue light. Research in a limited number 
of our SLS patients showed normal plasma levels of lutein and zeaxanthin, therefore 
excluding gastrointestinal or dietary causes of carotenoid deficiency (unpublished 
data). A disturbed retinal macular pigment metabolism, presumably located within 
retinal Müller cells, appears the most probable reason for macular pigment deficiency 
in SLS. It is uncertain whether supplementation of carotenoids would be beneficial in 
SLS patients. Surely, normal plasma concentrations of lutein and zeaxanthin indicate 
that there is no strict bodily depletion of carotenoids. Furthermore, carotenoids 
undergo oxidation at the ocular level and form highly active aldehydes (carot-
enoid-derived aldehyde).22 In general, oxidation of aldehydes is disturbed in SLS 
patients. Supplementation of carotenoids in SLS might therefore lead to an 
accumulation of these toxic aldehydes due to insufficient breakdown and cause 
additional retinal damage. The absence of macular pigment increases the risk for 
light toxicity and may augment the development of macular degeneration. 
Gene therapy
In 2006, Haug et al. demonstrated the in vitro capability of FALDH activity induction 
through gene transfer using an adeno-associated viral vector in keratinocytes of two 
SLS patients.23 FALDH activity was augmented up to 60–70 % of normal activity 
(measured by standardized procedure using octadecanol as substrate). Histologically, 
reduced thickness of the stratum corneum was observed, which may clinically relate 
to improvement of ichthyotic skin in these patients. Strict limitations and cautions are 
mentioned by the authors regarding the scientific interpretation of this observation. 
Also, it is questionable whether these in vitro results are reproducible in vivo when 
tested, for example, in an appropriate animal model. Furthermore, the achievability of 
gene transfer into neuronal cells in SLS has not yet been studied. Although in vitro 
results are promising, this illustrates that FALDH activity induction through gene 
transfer needs more research into feasibility and clinical implications in vivo using 
animal models. The difficulty here is that, to the best of our knowledge, such animal 
models do not exist at this time. 
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Conclusions 
Primarily based upon findings from our own study cohort, we here provided a state-
of-the-art synopsis of current pathophysiological concepts in SLS to guide the 
clinician when making the diagnosis SLS. We show the distinctive clinical features in 
SLS and provide a cross-sectional overview of psychomotor functioning, which helps 
the clinician when counseling parents of new SLS patients. By focusing upon 
treatment strategies and research topics in SLS, we provide greater insight into 
pathophysiological concepts that play part in SLS and help clinicians understand its 
current challenges. 
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Clinical features
Daily functioning
In Chapter 2 and Chapter 3 of this thesis we studied daily functioning in our cohort of 
SLS patients. Regarding motor functioning, we found that most of our patients had 
limitations, and these limitations were present in all gross motor dimensions, except 
for lying and rolling. Most of the patients suffer from moderate intellectual disability 
which typically seems to be limited around 5–6 years of developmental age. Though 
SLS is a neurometabolic disorder and the ongoing accumulation of both fatty aldehydes 
and alcohols in tissues is considered one of the principal causative mechanisms, 
the level of daily functioning remains rather stable throughout patients lives.1 
We previously reported that SLS behaves clinically in a non-progressive way and its 
course has more of a resemblance to the course seen in patients with cerebral palsy. 
 Currently our study cohort contains 31 patients aging from 7-60 years some of 
which we have been following for almost 2 decades yet daily functioning still remains 
rather stable. Surely some patients encounter complications such as scoliosis and 
spontaneous fractures that impair daily functioning but these usually result from their 
longstanding spasticity rather than indicate progressive disease.
Ophthalmological features
Though SLS seems to behave in a non-progressive way when cognitive and motor 
performances are brought into consideration, this may not apply to the maculopathy 
seen in these patients. 
 In Chapter 4 we studied the maculopathy in SLS and proposed a differentiation 
of the optical coherence tomography (OCT) results into 3 forms, namely, mild, 
moderate, and severe. In general, patients who were severely affected on OCT showed 
intense changes on previously performed cerebral magnetic resonance spectroscopy, 
indicating a positive relationship. The follow-up on OCT in 3 of 14 study participants 
was unable to detect significant changes within fifteen months of observation. We 
postulated that foveal atrophy in SLS may be a time-consuming process and a 
prolonged follow-up period in a larger number of patients may be necessary to detect 
disease progression. 
 In addition, the crystalline maculopathy in SLS showed a significant lack of central 
macular pigment (MP). The lacking macular pigment resulting in poor protection from 
high-energetic photons may explain some of the clinical features in SLS (e.g. 
photo phobia) but may also play an important part in progressive degenerative 
processes, leading to macular thinning and pseudocyst formation. 
 Recently, one of our patients (female, 31 years) suffered from a severe, 
consecutive loss of visual acuity in both eyes. Evaluation revealed an exudative 
macular degeneration not previously encountered in other SLS patients. It is yet 
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unclear if this results from the ongoing accumulation of FALDH-related metabolites 
and therefore an indication of a progressive disease. In addition, the lack of macular 
pigment in SLS may add to increased retina vulnerability due to light toxicity. If so, 
therapeutic interventions may aim to protect the retina from light in order to slow down 
or even stop the degenerative processes within the retina.
 Oxidative stress from high energetic photons is thought to play an important part 
in the development of age-related macular degeneration.2 When lutein is combined 
with zeaxanthin macular pigment is formed; eliminating lutein from the diet resulted in 
signs of early retinal degeneration in primates.3 One could postulate that longstanding 
MP deficiency and subsequent light toxicity is responsible for the development of 
macular degeneration in the aforementioned patient. Also, the motor and cognitive 
performances in this patient have not deteriorated overtime; therefore no other signs 
of progressive disease due to the ongoing accumulation of fatty alcohols and 
aldehydes are currently seen in this patient. Further research is needed to find out 
what kind of a role MP deficiency plays in SLS maculopathy and what complications 
can evolve from this deficiency. 
 Histological analysis of the retina in two patients with macular telangiectasia - a 
disorder in which patients gradually lose macular pigment - showed the absence of 
Müller cells. In addition to our previous findings this analysis points to a pivotal role of 
the Müller cell in macular pigment metabolism. 3-5 Results from future SLS studies 
should be compared with studies from patients with macular telangiectasia to 
increase further development in pathophysiological concepts. 
 Light protection by filtering glasses has been studied in adults in order to either 
prevent further macular degeneration or to improve visual functioning but results 
remained inconclusive.6
 In SLS, MP deficiency and subsequent light toxicity probably already develops in 
childhood which is much earlier than patients with adult macular degeneration or 
macular telangiectasia. It may be useful to early apply short-wavelength filtering 
glasses for SLS patients to reduce toxic light effects and to prevent the worsening of 
maculopathy which can lead to macular degeneration. Future studies are needed to 
back up these postulations.
Dermatological features
In Chapter 6 we studied the effects of inhibition of leukotrienes upon the skin. Although 
we could only find a convincing clinical response to the treatment with zileuton in one 
patient, this response was in such a way that a positive relationship between 
leukotrienes formation by keratinocytes and pruritus in our patients must exist. 
Difficulties in demonstrating effects of zileuton presumably are dosage related. The 
following factors need to be considered: (1) the off-label usage of zileuton (namely 
dose-finding data are from asthmatic patients); (2) different cell types involved 
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(namely mast cells versus keratinocytes in asthmatic and SLS patients respectively); 
and (3) different end organs that react (namely the lung versus the skin in asthmatic 
and SLS patients respectively). Further studies of pharmacokinetic–pharmacody-
namic relationships of zileuton are needed in SLS to find out what dosage is sufficient 
to decrease dermal leukotrienes formation.
What causes keratinocytes to produce more leukotrienes in SLS? Aside from a 
defective water barrier in the stratum corneum which resulted from abnormal lamellar 
body formation, the skin in SLS also displays a reduced level of ceramides.7 
Ceramides also play a crucial part in water barrier formation and thus not only is the 
FALDH-related accumulation of alcohols and aldehydes responsible for the 
ichthyosiform phenotype in SLS but also the deficiency of ceramides. Interestingly 
enough, patients with atopic dermatitis also demonstrated to have a markedly 
reduced amount of ceramides. Ceramide is synthesized from sphingomyelin in the 
stratum corneum by sphingomyelinase. In patients with atopic dermatitis however, 
sphingomyelin metabolism is altered. Instead of being hydrolyzed into ceramide, 
sphingomyelin is preferentially hydrolyzed into sphingosyl phosphorylcholine (SPC) 
by a different enzyme. The result is not only a deficiency of ceramide but also an 
increased production of SPC in the stratum corneum of these patients.8 Moreover, 
intradermal SPC injection was demonstrated to produce itch-associated responses 
in a mouse model and cultured mouse keratinocytes significantly increased the 
production of leukotriene B4 upon exposure to SPC.9 Presumably, SPC exposure 
triggers keratinocytes to produce LTB4 thereby causing pruritus. In addition, treatment 
with zileuton after SPC exposure, led to a dose-dependent reduction of scratching, 
again confirming the causative relationship between LTB4 and pruritus.
 Perhaps in SLS the sphingomyelin metabolism is also altered in an atopic 
dermatitis type manner, thereby explaining the lack of extracellular ceramide (also 
contributing to the defective water barrier) and an increased leukotriene formation in 
the stratum corneum causing pruritus. This may yield other future therapeutic 
approaches for new drugs targeting the SPC receptor of keratinocytes or inhibiting 
the enzyme responsible for SPC formation from sphingomyelin.
 However, data from SPC measurements in SLS skin are lacking, and thus further 
research is needed to back up these findings.
 In addition to these findings, intracellular ceramide catabolism generates sphin-
gosine-1-phosphate (S1P) which is degraded into hexadecenal to be oxidized by 
FALDH into fatty acids.10 In SLS this ceramide catabolism may also be disturbed due 
to a defective breakdown of hexadecenal and subsequent accumulation of S1P. 
However, due to apparent extracellular ceramide deficiency in SLS, it seems unlikely 
that large amounts of S1P are generated at the intracellular level.
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Biochemical features
As discussed in the general introduction section of this thesis, FALDH is involved in 
the breakdown of many substrates from several diverse lipid pathways.
 To what extent the defective breakdown of these substrates contributes to the 
clinical signs and symptoms in SLS remains largely to be elucidated. As stated 
previously, it is generally believed that clinical symptoms evolve from one of the 
following two factors: (1) an accumulation of (toxic) lipid metabolites which cannot be 
metabolized by FALDH (or FAO), their diversion into other metabolic products or a 
combination of both, or (2) the deficiency of critical fatty acid products of FALDH. 
However, it is not likely that all substrates that depend on FALDH for their breakdown 
contribute equally to the clinical picture seen in SLS. Also, there may be other unknown 
substrates that are relevant and cause symptoms as shown in Figure 1. 
Future biochemical studies will contribute to a growing insight into FALDH and its role 
in SLS. As was demonstrated by the histopathological and biochemical parallels seen 
in both macular telangiectasia and atopic dermatitis, it is important to use different 
disease models to gain a greater insight into SLS.  
Figure 1   Lipid pathways involved in SLS. Adapted from Rizzo et al.10
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Genetic features
As was stated previously, more than 70 different mutations in the ALDH3A2 gene 
have been identified in patients with SLS to date. Despite this rather variable genotype, 
the phenotype in SLS is usually quite homogeneous. Recently, Rizzo et al. reported 
a patient with a very large deletion to the ALDH3A2 locus, leading to a complete loss 
of ALDH3A2. Yet, the phenotype remained within the range of what might be expected 
in SLS.11 
 However, genetic testing is usually performed in those patients with an already 
high clinical suspicion of having SLS. This may create a bias in our view of the clinical 
phenotype in SLS. It is imaginable that with new techniques such as whole exome 
sequencing being performed in patients with different signs and symptoms, the 
clinical spectrum of SLS symptoms changes. By using exome sequencing it is also 
possible to detect other genetic defects in new disease entities that resemble SLS 
clinically but lack FALDH deficiency. This was recently demonstrated in two cases 
with SLS-like symptoms but normal FALDH activity. Exome sequencing revealed 
mutations in the ELOVL4 gene, coding for fatty acid elongases which are enzymes 
involved in the synthesis of very-long-chain fatty acids (which in turn are components 
of sphingolipids and phospholipids).12 
 It is possible that in the future other mutations in different genes are found that 
produce a SLS-like phenotype. This will again generate a greater understanding of 
the complex biochemical pathways involved in SLS.
Treatment strategies
In general, the current treatment is mainly symptomatic. Nevertheless, aside from 
zileuton, several new treatment concepts in the past years have evolved from a greater 
understanding on the pathophysiological mechanisms responsible in SLS. 
Bezafibrates
The expression of the ALDH3A2 gene is regulated by a transcription factor called 
peroxisome proliferator activated receptor α (PPARα).13 PPARα is part of a family of 
PPARs which are ligand-inducible transcription factors belonging to the family of 
nuclear hormone receptors. It binds to a specific PPARα response element in the 
promoter of the ALDH3A2 gene leading to the up regulation of its transcription. 
Several ligands are known to be capable of activating PPARα among which are 
natural ligands (such as phytanic and pristanic acid) and also pharmacological 
agents (such as bezafibrate).14,15  
 Interestingly, mouse model studies have shown that a phytol-enriched diet is 
capable of the activation of PPARα through increased levels of the phytol metabolites 
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phytanic and pristanic acid in plasma.16 A subsequent induction of ALDH3A2 gene 
expression however has not been studied.
 Bezafibrate, a drug used for treatment of hyperlipaedemia, has also been 
demonstrated to act as a PPARα ligand and has the in vitro capability of inducing 
ALDH3A2 expression and subsequent improvement of residual FALDH activity - 
measured using phytol as substrate - in fibroblasts from SLS patients.15 This can only 
be accomplished in patients with some residual FALDH activity which occurs only in 
a minority of the genotypes in SLS and particularly in some specific missense 
mutations. Potential therapeutic effects of bezafibrate treatment in selected SLS 
patients should be part of future research.   
Gene therapy
As was discussed in Chapter 7, the in-vitro induction of FALDH activity in 2006 was 
accomplished in keratinocytes by gene transfer using an adeno-associated viral 
(AAV) vector.17 Recently, advances have been made towards a safer and more 
effective intraocular administration of AAV vectors in humans underlining possibilities 
in retinal gene therapy for inherited retinopathies.18 Previously, research in rats 
detected a new AAV vector serotype which is capable of highly selective Müller cell 
transduction upon intravitreal injection.19 Combining these findings, one could 
postulate that in SLS there are future possibilities to selectively induce FALDH activity 
in Müller cells using intravitreal-administered AAV vectors by gene transduction. Of 
course, many limitations are to be made, such as the use of different vectors and the 
still unclear pathophysiological concepts of the SLS maculopathy and Müller cell 
involvement specifically. Future studies are needed to investigate the possibilities of 
retinal gene therapy in SLS.
What’s next?
This thesis on Sjögren-Larsson syndrome is published almost 60 years after the 
original description was first drawn up in 1956. Although insight into underlying 
pathophysiological mechanisms has increased vastly since 1956, there are still many 
questions that need to be addressed. The work presented in this thesis could not 
have been accomplished without very active patient participation in our clinical trials. 
This can be the key to success for future clinical trials. Real progress in quality of life 
in SLS can be made if researchers and patients define and prioritize study goals 
together. Shared decision making in SLS research is the next chapter!
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Summary
The Sjögren-Larsson syndrome (SLS) is hallmarked by an original triad of clinical 
symptoms, namely ichthyosis, spasticity and mild-to-moderate intellectual disability. 
During past decades studies with partially genetically unrelated patients revealed 
additional clinical features such as premature birth, a peculiar crystalline maculopathy 
and impaired speech-language performance.   
 A deficient microsomal fatty aldehyde dehydrogenase (FALDH) underlies SLS. 
FALDH is part of the fatty alcohol nicotinamide adenine dinucleotide oxidoreductase 
complex (FAO) and catalyzes oxidation of many different medium- and long-chain 
fatty aldehydes into fatty acids. Deficiency of FALDH results in the accumulation of 
fatty aldehydes and fatty alcohols in body tissues. Besides its important role in fatty 
alcohol metabolism, FALDH is also involved in the breakdown of many other 
substrates among which are the pro-inflammatory leukotrienes. 
 It is generally believed that clinical symptoms evolve from one of the following 
two factors: (1) an accumulation of (toxic) lipid metabolites which cannot be metabolized 
by FALDH (or FAO), their diversion into other metabolic products or a combination of 
both, or (2) the deficiency of critical fatty acid products of FALDH.  
 The genetic basis of SLS is found in the FALDH gene, recently renamed ALDH3A2 
and located on chromosome 17p11.2. By now, more than 70 different mutations in the 
ALDH3A2 gene have been identified in SLS patients originating from about 120 different 
families. Most mutations result in a complete loss of catalytic activity of FALDH, although 
there are several (missense) mutations associated with residual FALDH activity.
Part ONE of this thesis focuses on the daily functioning of patients with SLS. The 
purpose of this part is to provide patients, parents and clinicians a further insight into 
the clinical course of SLS and to provide prognostic information on motor performance 
and intellectual disability which can be helpful in counseling patients and parents. 
 Chapter 2 describes data from a cross-sectional study of motor performance 
and everyday functioning in 17 patients with this rare disorder. Nine female and eight 
male patients with SLS (age range 1–35 years) were investigated. Data were obtained 
by structured interview (with parents and SLS patients) and physical examination. 
Motor performance was measured by the Gross Motor Function Measure; everyday 
functioning was assessed using the Pediatric Evaluation of Disability Inventory and 
the Vineland Adaptive Behavior Scale. In most patients, spasticity was bilaterally 
present in hamstrings, hip adductors, and gastrocnemic muscles. All participants 
above 7 years of age had contractures in the lower extremities. Limitations were 
present in almost all gross motor dimensions. Nevertheless, on the activity level 
these children and young adults were able to move around in the community mostly 
using wheelchairs. Patients had developmental ages below their chronological age. 
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Limited communication, social interaction with peers, and restricted participation had 
additional impact upon daily functioning. During this cross-sectional study motor 
performance and everyday functioning remained rather stable in patients, referring to 
the absence of signs of progressive disease.
 Chapter 3 provides a detailed insight into cognitive functioning and speech-lan-
guage pathology in SLS. Cognitive functioning was assessed in 16 patients with SLS 
using different neuropsychological tests. Speech-language pathology was studied 
focusing on dysarthria, oral motor functioning, speech intelligibility and language 
development. Potential correlations between speech-language pathology and other 
neurological symptoms (e.g. spasticity) were studied. Doing so, we found that the 
median cognitive developmental age in this study group was 5 (years);8 (months) 
(n =13; range 3;5 – 8;0) years of age. Besides this intellectual impairment, a variable 
degree of mainly pseudobulbar dysarthria was found. Speech intelligibility was 
influenced by dysarthria, but was also related to language pathology. Subsequently 
we studied potential correlations between the speech-language pathology found in 
this study and co-existing impairments on motor- and everyday functions (as found 
in the study described in Chapter 2). No intra-individual correlation between the level 
of motor functioning and the level of dysarthria or cognitive development was 
observed in patients. We concluded that dysarthria and language problems are 
important factors in daily life functioning of patients with SLS. Based upon the clinical 
profile found in this study, we recommended early speech-language therapy in order 
to optimize speech-language development in patients with SLS. 
Part TWO focuses on the pathognomonic crystalline maculopathy seen in the eyes 
of SLS patients. This maculopathy, which develops gradually within early childhood, 
can easily be observed by ophthalmoscopy. The crystalline retinal dots are clinically 
scattered throughout the peri-fovea. Although the central fovea seems to be uninvolved by 
crystal deposition, virtually all SLS patients have subnormal visual acuity. Little is 
known about what specific retinal cell types are pathophysiologically involved in SLS. 
By studying this peculiar maculopathy we gained further insight into the retinal lipid 
metabolism and cells involvement in the development of the SLS-maculopathy. 
Chapter 4 studies morphologic changes in the retina by optical coherence 
tomography (OCT). OCT provides high-resolution images of the retina enabling 
researchers to zoom-in on specific retinal cell layers. Doing so, we expected to be 
able to specify the layers involved in the SLS-maculopathy thereby gaining further 
insights into the possible cell types involved. 
 Full ophthalmologic examination and OCT was performed in all study patients 
(N=14; 27 eyes studied). We found that, besides the expected peri-macular crystals 
in the eyes of all study participants detected with ophthalmoscopy, macular morphology 
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and reflectivity were significantly changed on OCT compared with healthy eyes. 
Focal hyperreflectivities were found within the peri-foveal ganglion cell layer and the 
inner plexiform layer that corresponded to the clinical localization of retinal crystals. 
These layers are mainly composed of axons and dendrites of ganglion cells and 
retinal interneurons. 
 The arrangement of crystals both on OCT and fundoscopy suggests involvement 
of the peri-foveal ganglion cells in the deposition of abnormal lipids in SLS. 
 More interestingly, a cystoid foveal degeneration on OCT was present in the 
majority of patients with SLS (18/27 eyes, or 67% of all eyes studied), varying from 
multiple microcystoid spaces to cystoid foveal atrophy. The cystoid changes seemed 
to be located in the outer plexiform layer and inner nuclear layer of the retina. The 
inner nuclear layer mainly contains nuclei and cell bodies of Müller glia cells whereas 
the outer plexiform layer is composed of synapses between photoreceptors and 
horizontal cells or bipolar cells and the cytoplasm of Müller glia cells. The typical 
localization of the cystoid spaces in our patients, together with the only mild-to- 
moderate loss of visual acuity, suggests a major affection of the foveal Müller cells 
and not the photoreceptors. 
 We were unable to detect significant changes within fifteen months of observation 
in 3 of 14 study participants. Therefore, we believed that foveal atrophy in SLS may be 
a time-consuming process and a prolonged follow-up period in a larger number of 
patients may be necessary to illustrate disease progression.
 Chapter 5 continues the studying of the peculiar maculopathy in SLS. It was 
noted that the macula of SLS patients lacks the normal dark-yellowish appearance, a 
feature that had not been appreciated fully previously. To decide whether an altered 
distribution or concentration of macular pigment (MP) could be responsible for this 
changed appearance, two different techniques were used in the study presented in 
this Chapter: (1) fundus autofluorescence (FAF) providing qualitative estimates of MP 
and (2) the novel macular pigment reflectometer (MPR) providing quantitative 
estimates of MP. Data were obtained from twenty-eight eyes of 14 SLS patients. 
Fundus autofluorescence images of SLS patients lacked the typical attenuation of 
macular FAF signal as expected in normal eyes. Mean foveal MP levels measured by 
MPR showed significantly lower values in SLS patients (0.10±0.07) than in healthy 
individuals (0.69±0.17; P<0.001, Student t test). This led to the conclusion that SLS 
patients must lack macular pigment. 
 As stated in Chapter 4, the crystalline deposits seen with ophthalmoscopy in SLS 
patients seemed to be located mainly in the ganglion cell layers and inner plexiform 
layer. Thus far, the biochemical nature of the glistening dots remains unknown; 
however, the site of their location on OCT corresponds with the histological position 
of MP in the normal retina. This co-localization suggests a relationship between the 
formation of intraretinal crystals and the absence of MP.
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 MP consists of a mixture of 2 dietary carotenoids, namely lutein and zeaxanthin. 
The human body is unable to synthesize any carotenoids, and therefore is completely 
dependent on dietary carotenoids, including lutein and zeaxanthin. Lutein and zeaxanthin 
are absorbed by intestinal mucosal cells and incorporated into chylomicrons that are 
secreted into the lymphatic system and subsequently enter the circulation. Hepatic 
cells incorporate the carotenoids from the chylomicrons into lipoproteins that facilitate 
further transport of the carotenoids to the various body tissues. Transportation, 
distribution and uptake of plasma lipoproteins is regulated by apolipoproteins that 
are produced by many organs, including the liver. Interestingly, Müller cells may as 
well play a part in macular pigment metabolism. Müller cells produce Apolipopro-
tein-E which is known to play a part in the targeted uptake of lutein and zeaxanthin 
from plasma and incorporation within the retina. Therefore, defective functioning of 
Müller cells may lead to a disturbed retinal MP metabolism which could be the 
underlying reason for MP deficiency in SLS.
Part THREE focuses on the skin. Epidermal dysfunction in SLS is rather complex 
since it contains various FALDH-dependent lipid pathways and hence it offers 
multiple potential approaches to reduce cutaneous symptoms. Previously, Willemsen 
et al. showed an association between pruritus and elevation of pro-inflammatory 
leukotriene B4 (LTB4), which is also FALDH-dependent for its breakdown. In SLS, 
elevation of dermal LTB4, by either increased production or defective breakdown or 
a combination of both, probably plays an important role in its dermatological 
phenotype.
 Chapter 6 describes results from a prospective, randomized, double-blinded 
and placebo-controlled trial studying the effect of blocking leukotrienes synthesis 
upon the general skin condition and especially pruritus in 10 patients with SLS. Erythema, 
desquamation, lichenification and excoriations were studied complemented with a 
Physician Global Assessment (PGA) of the skin. Primary outcome measures were 
changes during treatment with zileuton. Also, self-reported visual analogue scales 
(VAS) for pruritus and excoriations were studied. Individual data analysis showed a 
consistent and convincing response to treatment in one patient. This corresponded 
to findings from previous studies relating to the use of zileuton in SLS. Also, though 
only a minority of patients seems to respond to treatment, they can easily be detected 
and will experience a significant improvement in quality of life. We thus suggested a 
therapeutic trial with zileuton during 4-6 weeks in SLS patients ≥5 years, especially 
when medical treatment for severe pruritus is warranted. If no clear beneficial 
response to zileuton is noted, treatment should be discontinued. 
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Part FOUR gives a state-of-the-art synopsis of current pathophysiological concepts 
in SLS. 
 Chapter 7 focuses on clinical practice. Distinctive clinical features in SLS are 
reviewed in order of appearance together with diagnostics and treatment options. 
Furthermore, current and future treatment strategies are discussed to render a 
comprehensive review of the topic. 
 Chapter 8 presents a discussion on current insights and future perspectives 
focusing on research questions. Consecutively, challenges in regard to clinical-, 
biochemical- and genetic SLS features are discussed followed by possible future 
treatment modalities. 
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Samenvatting in het Nederlands (Dutch summary)
Het Sjögren-Larsson syndroom (SLS) wordt gekenmerkt door een drietal oorspronkelijk 
beschreven hoofdsymptomen: ichthyosis (droge en schilferende huid met verdikking 
van de opperhuid), spasticiteit en een verstandelijke beperking. Hiernaast zijn er de 
afgelopen jaren nieuwe symptomen ontdekt zoals prematuriteit (vroeggeboorte), zeer 
specifieke afwijkingen aan de retina (netvlies) en een belemmering in taal-/spraak-
ontwikkeling.
 SLS wordt gerekend tot de zogenaamde neuro-metabole aandoeningen. Symptomen 
komen voort uit een afwijking in de stofwisseling van cellen. Deze afwijking betreft 
een tekort aan het enzym fatty aldehyde dehydrogenase (FALDH). Dit enzym is in 
cellen onder andere verantwoordelijk voor het omzetten van specifieke vetten (fatty 
aldehydes) in vetzuren (fatty acids). Door het tekort aan FALDH ontstaat er stapeling 
van deze fatty aldehydes in het lichaam. Naast de rol in het vet metabolisme speelt 
FALDH ook een rol bij de afbraak van andere stoffen zoals leukotriënen (stoffen die 
betrokken zijn bij ontstekingsreacties). Het wordt algemeen aangenomen dat de 
symptomen in SLS voortkomen uit een van de volgende twee factoren: (1) opeen-
stapeling van (toxische) stoffen die niet door FALDH kunnen worden afgebroken en 
al dan niet worden omgezet in andere (toxische) stoffen, of (2) het tekort aan essentiële 
stoffen die normaliter geproduceerd worden door FALDH.
 Het tekort aan FALDH wordt bij het SLS veroorzaakt door een erfelijke afwijking. 
Door een afwijking op chromosoom 17 is een verandering (mutatie) ontstaan in het 
zogenaamde ALDH3A2 gen. Dit gen is verantwoordelijk voor de productie van FALDH 
en kan dat door deze mutatie niet of in veel mindere mate uitvoeren. 
Dit proefschrift bestaat uit vier delen.
 In het eerste deel wordt het dagelijks functioneren van patiënten met SLS 
beschreven. De doelstelling is hierbij om meer inzicht te verkrijgen ten aanzien van de 
spasticiteit, de verstandelijke ontwikkeling en de taal-/spraak problematiek. De 
informatie die hieruit voortkomt, kan worden gebruikt om patiënten, ouders en 
behandelaars meer inzicht te geven in het te verwachten ziektebeloop bij jonge 
patiënten met SLS. Hoofdstuk 2 beschrijft een studie naar het functioneren van 17 
patiënten met SLS. In deze studie werd gekeken naar het motorisch functioneren in 
algemene zin en de invloed die dit had op het dagelijks leven. De meeste patiënten 
hadden als gevolg van spasticiteit aanzienlijke contracturen aan (met name) de 
benen. Dit leidde tot aanzienlijke beperkingen in mobiliteit. Toch bleken vrijwel alle 
patiënten in staat om zichzelf voort te bewegen met gebruik van een rolstoel. Het 
dagelijks functioneren werd verder beperkt door een matige verstandelijke beperking 
en beperking in de communicatie door belemmering van spraak. In de studie 
weergegeven in hoofdstuk 3 werd deze belemmering in taal-/spraak ontwikkeling bij 
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16 patiënten met SLS verder bestudeerd. Belemmerende factoren werden in kaart 
gebracht. Naast de verstandelijke beperking (en de daarmee samenhangende, 
belemmerde taalontwikkeling) werd er een spraakstoornis (dysarthrie) gevonden die 
voortkomt uit spasticiteit van spieren in het mondgebied (pseudobulbaire dysarthrie). 
De kwaliteit en de verstaanbaarheid van de spraak werd hiermee in negatieve 
zin beïnvloed. De verstandelijke beperking werd in kaart gebracht, waarbij een 
ontwikkelings leeftijd van gemiddeld 5 jaar en 8 maanden werd vastgesteld, hoewel 
de werkelijke leeftijd van deze groep 17 jaar en 10 maanden bedroeg. 
In deel 2 worden de voor SLS kenmerkende afwijkingen aan het netvlies (retina) 
beschreven. Het netvlies kan worden gezien als een onderdeel van het centraal 
zenuwstelsel en meer kennis over afwijkingen aan het netvlies kan daarom wellicht 
meer inzicht geven ten aanzien van afwijkingen in de hersenen en onderliggende 
problemen in de stofwisseling. 
 Patiënten met SLS hebben te maken met een verminderd zicht (visus) en 
verdragen geen fel licht (fotofobie). Het netvlies bij SLS-patiënten vertoont al in de 
eerste levensjaren afwijkingen in de vorm van kleine kristallen die gerangschikt zijn 
rondom de gele vlek (macula). Deze kristallen kunnen met oogheelkundig onderzoek 
(spleetlamp) goed worden waargenomen. Het is onduidelijk hoe deze kristallen 
precies ontstaan en welke rol zij spelen bij het zicht van patiënten met SLS. De studie 
weergegeven in hoofdstuk 4 bestudeerde het netvlies van SLS-patiënten met behulp 
van een relatief nieuwe techniek: optical coherence tomography (OCT). Deze techniek 
maakt gebruik van lichtgolven met een zeer hoge resolutie om (net als bij de geluids- 
golven van echografie) een dwarsdoorsnede van weefsels te verkrijgen.
 Het netvlies is opgebouwd uit 10 afzonderlijke lagen en bevat ondermeer zoge naamde 
fotoreceptoren (staafjes en kegeltjes), zenuwcellen en steunweefselcellen. Met behulp van 
OCT zijn deze verschillende lagen (en eventuele afwijkingen in die lagen) goed te 
visualiseren. Door in kaart te brengen in welke specifieke lagen van het netvlies er bij 
SLS-patiënten afwijkingen worden gezien, groeit het inzicht in onderliggende pathologie. 
 De ogen van 14 SLS-patiënten werden op deze wijze onderzocht. Ter plaatse van 
de retinale kristallen werden met OCT kenmerkende reflecties gezien vanuit de 
zogenaamde ganglioncellaag. Dit type cel vormt de schakel tussen de fotoreceptoren 
en de oogzenuwcellen. Het is aannemelijk dat ganglioncellen betrokken zijn bij het 
ontstaan van de kristallen in SLS.
 Naast deze reflecties werd er bij de meerderheid van de patiënten ook een 
degeneratie (verlies van weefsel) van het centrale deel van de macula (fovea) gezien. 
De cellagen die verloren waren gegaan, bevatten voornamelijk Müller cellen, hetgeen 
steuncellen zijn die in contact staan met de fotoreceptoren. Het is daarom goed 
mogelijk dat (problemen in) de Müller cellen een belangrijke rol spelen bij het 
veroorzaken van de oogheelkundige afwijkingen in SLS.
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 Hoofdstuk 5 betreft een vervolgstudie. Tijdens de eerdere studie was opgevallen 
dat de macula (gele vlek) van SLS-patiënten een duidelijk blekere kleur heeft in 
vergelijking met die van gezonde personen. Het netvlies krijgt zijn oranje kleur door 
een aparte laag van het netvlies (retinapigment epitheel laag). De macula dankt zijn 
specifieke gele kleur aan maculapigmenten (opgebouwd uit zogenaamde carotenoïden) 
die vrijwel alleen daar voorkomen. Er werd aangenomen dat de blekere kleur van de 
macula bij SLS-patiënten voortkomt uit afwijkingen in het maculapigment. Het 
maculapigment werd bestudeerd bij 14 SLS-patiënten middels het verrichten van 
kwalitatieve autofluorescentie metingen (‘fundus autofluorescence imaging’; FAF) en 
kwantitatieve pigment reflectie metingen (‘macula pigment reflectometer’; MPR). Hierbij 
werd aangetoond dat bij de onderzochte patiënten de hoeveelheid maculapigment 
in sterk verminderde mate aanwezig of geheel afwezig was. Deze zeer bijzondere 
bevinding zou de fotofobie, zoals aanwezig bij SLS-patiënten, goed kunnen verklaren. 
 Verder is bekend dat Müller cellen een belangrijke rol spelen bij het metabolisme 
van maculapigment. De uitkomsten van dit onderzoek geven daarmee een nieuwe 
aanwijzing dat deze cellen inderdaad aangedaan zijn door de stofwisselingsproblematiek 
in SLS.
Deel 3 van dit proefschrift beschrijft de huidafwijkingen bij SLS-patiënten. Zoals 
vermeld, hebben patiënten met SLS last van ichthyosis, die leidt tot een dikke 
opperhuid met veel schilfering. Dit is het duidelijkst waarneembaar aan de ellebogen, 
in de nek en op de romp. Patiënten hebben opvallend veel last van jeuk. Eerder 
onderzoek toonde aan dat het FALDH-gerelateerde vetmetabolisme ook in de 
opperhuid een rol speelt. Onderzoek bij andere huidaandoeningen toont verder een 
duidelijke relatie aan tussen leukotriënen en jeuk. FALDH is ook betrokken bij de 
afbraak van specifieke ontstekingstoffen (leukotriënen; LTB4). Het is daarom 
aannemelijk dat bij SLS stapeling van deze stoffen, hetzij door verhoogde productie 
dan wel door gestoorde afbraak (of een combinatie hiervan), in belangrijke mate 
bijdraagt aan het huidbeeld.
 Hoofdstuk 6 beschrijft de resultaten van een geneesmiddelstudie waarbij 
onderzocht werd of met het middel zileuton het huidbeeld bij SLS-patiënten verbeterd 
kan worden. Zileuton is een middel dat ondermeer gebruikt wordt bij astmapatiënten. 
Het remt de productie van leukotriënen. Gedachte is, dat er in de huid minder 
stapeling van deze leukotriënen optreedt (door remming van de productie) en dat 
hierdoor vooral de jeuk sterk kan afnemen. 
 De studieopzet was geblindeerd voor artsen en patiënten en er werd gebruik 
gemaakt van een placebo. Bij 10 patiënten werd het effect van zileuton op de huid 
bestudeerd met gestructureerde beoordelingen van de huid (door de onderzoeker) 
en zelfevaluaties (door ouders/verzorgers van patiënten). Een sterke vermindering 
van de jeuk werd bij 1 patiënt geconstateerd. De andere patiënten vertoonden geen 
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(overtuigende) reactie. Het is niet duidelijk waarom er slechts bij 1 patiënt een 
dergelijke reactie werd gezien. Dit is echter wel in lijn met bevindingen uit een eerdere 
studie. Bij huidige doseringen reageert slechts een minderheid van de SLS-patiënten 
op zileuton behandeling. Verdere bestudering van de relatie tussen de verstrekte 
dosis zileuton en het effect bij patiënten dient in de toekomst plaats te vinden. 
 Zileuton kan als een veilig middel aangemerkt worden. Omdat een eventuele 
positieve reactie bij patiënten duidelijk herkenbaar is en daarmee leidt tot verbetering 
van kwaliteit van leven, wordt een korte (proef)behandeling met zileuton aanbevolen 
bij SLS-patiënten die veel last hebben van jeuk.
In deel 4 wordt een uitgebreide samenvatting gegeven ten aanzien van de huidige 
inzichten rondom SLS. Hoofdstuk 7 beschrijft aan de hand van de symptomen bij 
SLS de verschillende diagnostische en therapeutische mogelijkheden. Dit is bedoeld 
om behandelaars van SLS-patiënten inzicht te geven in de huidige stand van zaken 
en hen zo te helpen deze patiënten wereldwijd goed te diagnosticeren en behandelen. 
In hoofdstuk 8 wordt de discussie met betrekking tot de huidige inzichten weergegeven 
en worden onderzoeksvragen voor de toekomst belicht. 
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Dankwoord (Acknowledgments)
Ik schrijf deze woorden enkele dagen voor kerstmis, de mooiste tijd voor reflectie 
en dank. 
Allereerst: dit proefschrift had nooit tot stand kunnen komen zonder de patiënten en 
hun ouders die aan de beschreven onderzoeken hebben meegewerkt. Zij verdienen 
dan ook de eerste woorden van dank. Mijn allereerste kennismaking met jullie was in 
2006 op de SLS-dag in de Hoogstraat te Utrecht. Ik zag een groep betrokken en 
zelfbewuste mensen. Een groep die gemotiveerd was om de kennis rondom het 
 Sjögren-Larsson syndroom te vergroten en die verantwoordelijkheid voelde om hier 
zelf ook een rol in te nemen. Voor mij als jonge onderzoeker was dit zowel inspirerend 
als ook wat beangstigend. Immers, het in ons gestelde vertrouwen bracht ook 
 verantwoordelijkheid met zich mee. De afgelopen jaren hebben we elkaar meermaals 
op dergelijke bijeenkomsten ontmoet en de stand van zaken met elkaar besproken. 
Samen hebben we gekeken naar nieuwe onderzoeksrichtingen en plannen gemaakt. 
Soms ging het snel en met relatief weinig tegenslagen maar regelmatig liep het 
anders en moesten plannen worden bijgesteld. Jullie flexibiliteit was daarbij cruciaal. 
Ik heb een groot respect ontwikkeld voor de wijze waarop jullie omgaan met de 
zorgen van het dagelijks leven en de missie om de kennis ten aanzien van SLS te 
vergroten, ook als dit niet direct iets oplevert voor de persoonlijke situatie. Dank voor 
jullie bijdrage en het in mij gestelde vertrouwen al die jaren. Ik besef me daarbij 
terdege dat het werk nog niet af is…  
Een groot woord van dank moet ook uitgaan naar mijn promotor, prof. dr. Michèl 
Willemsen. Het is jouw werk geweest dat ik mocht voortzetten. Ik weet nog goed hoe 
we hier de eerste keer over spraken onder het genot van een goed glas wijn bij jou 
thuis. En hoewel me nog veel onduidelijk was, kreeg ik wel direct een goed gevoel bij 
het onderwerp, de opzet, maar vooral jouw begeleiding. Het is een goede keuze 
gebleken. Ik heb veel mogen leren van je als onderzoeker, specialist en mens. Je 
prikkelende en kritische reflecties op mijn werk motiveerden telkens weer om verder 
te komen. De wijze waarop je patiënten betrok bij de richting en invulling van het 
onderzoek en je omgang met patiënten en collegae inspireerden mij keer op keer. Ik 
heb er veel van geleerd en het heeft bijgedragen aan de wijze waarop ik vandaag 
mijn vak uitoefen. Ik ben je hiervoor zeer dankbaar. Uiteindelijk heeft het promotietraject 
wel wat langer geduurd dan oorspronkelijk de bedoeling was, maar dat heeft er 
uiteindelijk ook toe geleid dat je vandaag als mijn promotor mag optreden!
148
Mijn copromotor, dr. Thomas Theelen, ben ik ook veel dank verschuldigd. Thomas, je 
bijdrage aan dit proefschrift is groter dan enkel de oogheelkundige studies. Naast je 
directe betrokkenheid bij de uitvoering van deze studies heb je ook op tal van andere 
momenten bijgedragen aan het werk dat nu voorligt. 
De leden van de manuscriptcommissie. Prof. dr. Hans Cruysberg. Beste Hans, je 
geldt als oogheelkundig expert op het gebied van zeldzame aandoeningen en hebt 
vanuit die rol betrokkenheid gehad bij de eerste stappen van mijn promotietraject. Ik 
ben dan ook vereerd dat je ook bij de afronding ervan betrokken bent als voorzitter 
van de manuscriptcommissie. Veel dank hiervoor.
Prof. dr. Oebo Brouwer. Beste Oebo, veel dank voor de grondige beoordeling van 
mijn manuscript.
Dr. Jos Draaisma. Beste Jos, ik vind het een grote eer dat je onderdeel uitmaakt van 
deze manuscriptcommissie en op die manier betrokken bent bij dit proefschrift. Je 
hebt een meer dan belangrijke rol gespeeld bij het halen van deze mijlpaal waarvoor 
ik je zeer erkentelijk ben. Je bevlogenheid als kinderarts is voor mij een grote 
inspiratiebron. Ik hoop dat we nog vele jaren samen vorm kunnen geven aan de 
algemene pediatrie in ons ziekenhuis. 
Collega kinderartsen drs. Petra Bot en drs. Ester Coolen. Samen met Jos geven we 
vorm aan de vakgroep algemene pediatrie in ons kinderziekenhuis. Ons adagium 
‘dingen voor elkaar mogelijk maken’ heeft ook geholpen bij de totstandkoming van 
dit proefschrift. Ik ben jullie veel dank verschuldigd voor het overnemen van allerhande 
(supervisie) taken en het bieden van ruimte om dit werk tot een goed eind te brengen. 
Ik hoop nog vele jaren samen met jullie vorm en inhoud te mogen geven aan 
academische algemene pediatrie!
Dank gaat ook uit naar collega en afdelingshoofd prof. dr. Kees Noordam. Beste 
Kees, de afgelopen jaren heb je mij op tal van momenten kansen en mogelijkheden 
geboden om mijzelf als kinderarts verder te ontwikkelen. Daarbij hoort zeker niet in 
de laatste plaats de mogelijkheid tot het volgen van de NFU-master opleiding in 
kwaliteit en patiëntveiligheid. Ik wil je danken voor het vertrouwen dat je daarbij 
steeds in mij hebt gesteld. 
Ik wil iedereen danken die op enigerlei wijze heeft bijgedragen aan het tot stand komen 
van de verschillende artikelen. In het bijzonder wil ik daarbij de volgende personen 
noemen.
Dr. Jan Willem Gorter en drs. Judith Verhoog voor het gedegen werk  bij het in kaart 
brengen van het motoor functioneren van SLS patiënten. 
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Marjo van Gerven en prof. dr. Ben Maassen voor de samenwerking bij ons onderzoek 
naar taal-/spraakontwikkeling.
Ik dank dr. Tos Berendschot en dr. Rob van der Veen voor de mogelijkheid die we 
hebben gekregen om  macula pigment metingen bij SLS patiënten te gaan verrichten. 
Prof. dr. Ron Wevers dank ik voor de zinvolle inhoudelijke discussies die wij in dit 
traject meermaals mochten hebben en de hulp van zijn laboratorium bij de uitvoering 
van ons onderzoek. Ing. Alexandra Versleijen en ing. Ed van der Heeft wil ik hierbij 
eveens noemen. Dank voor al het werk dat er is gaan zitten in de metingen van 
leukotriënen. 
Dr. Marieke Seyger en drs. Diane Bastiaans. Het heeft even geduurd maar uiteindelijk 
hebben we onze zileuton studie toch kunnen uitvoeren. Dank voor jullie meer dan 
noodzakelijke bijdrage hierbij. Dr. Nel Roeleveld dank ik voor haar waardevolle 
bijdrage aan het artikel.
  
Mijn collega in het werkplekmanagement, Margriet van Buuren. Al enkele jaren geven 
we samen vorm en inhoud aan het ‘duaal leiderschap’ van de medium care. Ik 
realiseer me dat alle drukte rondom de afronding van mijn proefschrift heeft gemaakt 
dat er minder tijd was dan voorheen. Ik wil je danken voor het begrip en geduld dat 
je hierbij hebt getoond. 
Ook alle collega specialisten, AIOS, teamleiders en verpleegkundigen van het Amalia 
kinderziekenhuis wil ik danken voor de samenwerking de afgelopen jaren. Hedwig 
Dillerop wil ik hierbij in het bijzonder noemen. Jouw gedegen werk in de coördinatie 
van de bedcapaciteit neemt mij dagelijks veel werk uit handen.
Medewerkers van het secretariaat wil ik danken voor de dagelijkse ondersteuning en 
flexibiliteit. In het bijzonder wil ik hierbij Sandra van Hugten en Wilma Kosman noemen. 
Sandra, je bent al jaren dé spil in onze vakgroep. Het lijkt een onmogelijke opgave 
om al onze taken en agenda’s te stroomlijnen en toch lukt je dit iedere keer weer. 
Wilma, je komst naar de Medium Care is van grote meerwaarde gebleken. Ik weet 
niet hoe je het doet maar iedere keer lukt het je weer om de meest onmogelijke 
opgaven binnen korte tijd geregeld te hebben.
Lieve familie en vrienden, ik wil jullie danken voor alles wat jullie voor mij betekenen en de 
rol die jullie direct of indirect hebben gehad bij het tot stand komen van dit proefschrift.
Ik wil graag beginnen bij mijn goede vrienden Martijn Bevers, Frank Eleveld, Johan 
Spierings, Olivier ten Hallers, Luc Roelofs en Stijn Hazenberg. ‘Vrienden zijn familie- 
leden zonder bloedverwantschap’ schreef Ronald Giphart en dat is zeker op onze 
vriendschap van toepassing. Wat is begonnen als vriendschap tijdens onze studie is 
150
inmiddels uitgegroeid tot een hechte band. We concludeerden laatst dat onze 
vriendschap in al die jaren ook onszelf heeft gevormd tot wie we nu zijn. Ik ben enorm 
trots op die band en de onvoorwaardelijke steun die ik van jullie ervaar. Ik realiseer 
me dat ik de afgelopen periode wat minder vaak op ‘de donderdagavond’ aanwezig 
ben geweest, ik zal snel een pot verf meenemen voor ons bankje!
Mijn schoonouders, Fred en Willeke Kok. Ik heb het enorm getroffen met jullie. Vanaf 
de eerste ontmoeting heb ik een warm, liefdevol welkom ervaren en dat is al die jaren 
zo gebleven. Ik ben afgelopen zomer aan de laatste onderdelen van dit proefschrift 
begonnen in jullie fantastische maison en France.  ‘La Coquille’ staat misschien wel 
het meest symbool voor jullie gastvrijheid en warmte. Met mijn hele schoonfamilie 
heb ik er een geweldige tweede familie bijgekregen. Ik hoop dat we nog vaak met 
elkaar van het leven mogen genieten! Nienke, ik zie uit naar jouw boekje, het gaat je 
ongetwijfeld lukken.
Mijn zus en zwager, Eveline en Bas Oonk. 
Bas, daar waar ik eerder schreef over vrienden die familie worden, geldt voor jou het 
omgekeerde. Je bent veel meer dan een zwager, je bent een echte vriend die onvoor-
waardelijk voor ons klaarstaat. Ik dank je voor alle mooie momenten die we samen 
hebben mogen delen en zie uit naar wat nog gaat komen!
Lieve Eveline, ik bewonder je om wie je bent en hoe je in het leven staat. Onze band 
heb ik eigenlijk altijd als sterk ervaren en je hebt meer invloed gehad op wie ik ben 
geworden dan je zelf vermoedelijk denkt. Ik ben er supertrots op dat je vandaag als 
paranimf aan mijn zijde staat! 
Mijn ouders, Arjen en Marjon Fuijkschot.
Lieve pap en mam. Dit proefschrift is aan jullie opgedragen. Het feit dat ik zover 
gekomen ben, komt voort uit de opvoeding die jullie me hebben gegeven. Ik ben jullie 
enorm dankbaar voor de  ‘kansen en mogelijkheden’ die jullie me  hebben geboden 
en de warmte en liefde die daar altijd aan ten grondslag lag. 
Pap, misschien is het samen reviseren van een compleet motorblok uit onze oude 
Volvo wel een mooie metafoor voor hetgeen ik van je heb geleerd: technisch inzicht, 
doortastendheid, volharding en vooral: uitdagingen niet uit de weg gaan.
Mam, ‘mannen zijn wat moeders van hen gemaakt hebben’, wordt wel gezegd. Daar 
valt niets op af te dingen.
Tot slot de 4 allerbelangrijkste mensen in mijn leven.
Lieve Hannah, mijn prinses. Wat heb je een boel liefde en levendigheid in ons huis 
gebracht. Je ijver, geduld en nieuwsgierigheid zijn geweldig om te zien. Ik ben heel 
benieuwd wat komen gaat en wees gerust, ik zal altijd je ‘pappa van de prinses’ blijven! 
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Lieve Jochem, jouw ondernemingszin en doorzettingsvermogen zijn nu al ongekend. 
Wat ben je toch een geweldig ventje. Ik zie ernaar uit om samen met jou ons motorblok 
te reviseren!
Lieve ……, jouw aankondiging heeft gemaakt dat dit werk een prachtige deadline 
kreeg. Ik zie uit naar je komst in ons gezin. Welkom kanjer!
So now I’ll sing into the world a simple message to my girl. Lieve Ellemieke, wat ben 
ik blij dat ik jou ben tegengekomen. Ik bewonder je iedere dag weer om wie je bent 
en hoe dat mij maakt. Je bent the change in mijn world. Het zonlicht in ons gezin komt 
écht van jou!
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Joris Fuijkschot was born on November 10th, 1977 in Eindhoven, the Netherlands. 
After finishing secondary school at the Lorentz Lyceum in Eindhoven (1996) he 
started Medical School at the Radboud University Nijmegen. In his final year he 
performed a research traineeship studying pulmonary development at the Hospital 
for Sick Children in Toronto, Canada. After obtaining his medical degree he started 
working as a resident in pediatrics at the Canisius-Wilhelmina hospital in Nijmegen 
(supervisor dr. Paul van Wieringen). His residency in pediatrics continued at the 
Radboud University Nijmegen Medical Center in 2005 (successive supervisors prof. 
dr. Louis Kollée and dr. Jos Draaisma). During this training he became especially 
interested in the Sjögren-Larsson syndrome and initiated his PhD project under the 
supervision of prof. dr. Michèl Willemsen and dr. Thomas Theelen.
 He finished his residency pediatrics in 2008 after which he started to work as a 
general pediatrician at the Department of Pediatrics of the Radboudumc Amalia 
Children’s hospital in Nijmegen. He became a full instructor of the European 
Resuscitation Council in 2009 and is at present still a member of staff at the Dutch 
Foundation for Emergency Medical Care of Children (‘Stichting Spoedeisende Hulp 
bij Kinderen’). In 2010 he became clinical director of the medium care pediatric wards 
of the Radboudumc Amalia Children’s hospital. During the past years he became 
especially interested in the subject ‘Patient Safety and Healthcare improvement’. In 
2014 he started the Master’s Degree program ‘Quality and Safety in Healthcare’ from 
the Netherlands Federation of University Medical Centers (Nederlandse Federatie 
van Universitair Medische Centra; NFU) under the supervision of dr. Hub Wollersheim 
and prof. dr. Paul Robben.
Joris is happily married to Ellemieke Kok. They are living their dreams in Nijmegen 
together with Hannah (18-09-2011), Jochem (20-09-2013) and ……   
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